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Abstract 
Intestinal macrophages in the lamina propria underlying the gut epithelium play an 
important role in gut homeostasis. They remove apoptotic cells and cellular debris and 
phagocytose and destroy invading pathogens and intestinal microbiota crossing the 
epithelium.  Infiltrating macrophages also play an important role in the pathogenesis of 
inflammatory bowel disease (IBD) by producing pro-inflammatory molecules such as 
TNF-alpha and metallo-elastase.  
In this work I developed a new method to isolate macrophages from human lamina 
propria mononuclear cells (LPMCs) using CD33 magnetic beads. I then carried out 
functional and phenotypic studies of these cells isolated from the lamina propria of 
control samples and from patients with either Crohn’s disease or ulcerative colitis.  
The use of additional marker CD14 enabled me to distinguish two populations of 
macrophages, namely CD33
+
CD14
- 
LPMCs,
 
the main intestinal macrophage population 
in the normal colon and CD33
+
CD14
+ 
LPMCs, predominant in the inflamed mucosa. 
Intestinal macrophages were also characterized for their expression of CD68, CD206 
and CD64. CD33
+
CD14
- 
LPMCs and CD33
+
CD14
+ 
LPMCs expressed CD68, the gold 
standard macrophage marker. 
CD206 is a macrophage mannose receptor and it is associated with a M2 macrophages 
phenotype. The numbers of CD206
+
 cells was higher in CD33
+
CD14
+
 cells of control 
and CD samples and to a lesser extent in CD33
+
CD14
+
 cells from UC patients. 
CD64 is the high affinity Fcgamma type I receptor (FcγRI) used to discriminates 
macrophages from dendritic cells. The numbers of CD64
+
 cells were markedly 
increased in the CD33
+
CD14
+
 cells of IBD mucosa and control subjects compared to 
CD33
+
CD14
-
 cells. 
4 
 
The ability of different macrophage subsets to make TNF- was also studied.  The 
number of CD33
+
CD14
+
 TNF-+ LPMCs was significantly increased in IBD patients 
compared to control subjects. Interestingly, using CD206, I found that the majority of 
CD33
+
CD14
+
CD206
+
 cells in IBD were TNFα+. Moreover CD33+CD64+ LPMCs 
produced significantly more TNF- compared to CD33+CD64- LPMCs which probably 
represent DCs. 
Since TNF- is first produced as a transmembrane molecule and then cleaved into 
soluble TNF- by the ADAM17/10 proteases, CD33 LPMCs were cultured with 
ADAM17/10 inhibitor, GW280264X, which induced a significant increase in 
transmembrane TNF-  and reduced release of soluble TNF-. Moreover reduced 
production of soluble TNF- and soluble IL-6R where found when biopsies of UC and 
CD patients were cultured with GW280264X. 
Finally, gene arrays on CD33 gut macrophages isolated from IBD patients and control 
subjects showed a dysregulated immune gene profile. IL-24 transcripts and protein were 
increased in IBD macrophages and when exogenous IL-24 was added to IBD mucosal 
biopsies cultured ex vivo there was an increase in promoted TNF- release. 
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1.1 Immune system  
1.1.1 The gut mucosal innate immune system 
The mucosal immune system is an integrated network of tissues and cells which 
protects the host from infections and environmental insults at the surfaces of the body. 
The crosstalk between various cell types of the innate and adaptive immune response, as 
well as the combination of physical, biochemical and mechanical mechanisms all 
contribute to the maintenance of immune homeostasis. With regards to the human 
gastrointestinal (GI) tract, the mucosal immune system is responsible for maintaining 
tolerance to the wide array of innocuous antigens in food, for maintaining a symbiotic 
relationship with the microbiota, and for providing the protective inflammatory 
responses which protect against enteric pathogens. A breakdown in intestinal immune 
homeostasis may lead to the onset of both food hypersensitivity and gut inflammation. 
The key components of the gut mucosal immune system are the various cell types in the 
epithelial layer and the immune cells populating the lamina propria, Peyer’s patches 
(PP), isolated lymphoid folicles and the mesenteric lymph nodes (MLNs). It is now 
widely appreciated that central players in shaping the features of the mucosal immune 
system are the microbial species inhabiting the intestinal lumen and the mucus layer 
(Kamdar et al., 2013). Indeed, the human GI tract is colonized by a diverse microbial 
population, consisting of approximate 100 trillion micro-organisms, including bacteria, 
fungi and viruses (Hooper and Gordon, 2001). The microbial component including 
luminal or mucosal-associated commensal bacteria is composed of 6–10 phyla and 
approximately 5,000 distinct species (Carvalho et al., 2012). The density of the luminal 
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microbes increases along the gastrointestinal tract, reaching up to 10
12
 bacteria per gram 
of luminal content in the colon (MacDonald et al., 2011). The mucus layer, together 
with anti-microbial peptides such as α-defensins released by Paneth cells, collectively 
forms the glycocalyx which traps invading micro-organisms and enables their 
expulsion. This process is facilitated by peristaltic movement. 
Below the glycocalyx, the first line of interaction with the environment is represented 
by the intestinal epithelium (Figure 1.1). This includes several cell types, including 
absorptive enterocytes, goblet cells which besides secreting mucus also produce trefoil 
peptides contributing to both barrier function and mucosal repair  (Mashimo et al., 
1996), enteroendocrine cells and Paneth cells. In addition to defensins and other anti-
microbial peptides, Paneth cells secrete  enzymes such as lysozyme and phospholipase 
A2, that can break down the cell walls of micro-organisms (Salzman et al., 2007). 
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Figure 1.1: Schematic representation of the gut epithelial barrier: the intestinal lumen is 
inhabited by a diverse microbial population, consisting of approximate 100 trillion micro-
organisms, including bacteria, fungi and viruses The mucus layer, together with anti-microbial 
peptides such as α-defensins released by Paneth cells, forms the glycocalyx which traps 
invading micro-organisms and enables their expulsion. The lamina propria lamina propria 
contain a large number of immunoglobulin A (IgA)+ plasma cells, T and B cells, macrophages, 
DCs. Lamina-propria DCs take up antigens from the lumen and present them directly to T cells 
and B cells, which can induce IgA class-switching and differentiation in situ. Secreted IgA is 
transported across the epithelium, where it serves as a first line of defence against pathogens and 
for the maintenance of gut-flora homeostasis.  
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The epithelium forms a physical barrier which is impermeable to most hydrophilic 
solutes in the absence of specific transporters. The function of tightly sealing the 
paracellular pathway between cells is mediated by the apical junctional complex, 
localized immediately below the microvilli of adjacent epithelial cells, by the adherens 
junctions and by the desmosomes (Turner, 2009). 
 
Both tight and adherens junctions are supported by a dense peri-junctional ring of actin 
and myosin that can regulate barrier function. The adherens junctions, along with 
desmosomes, provide the strong adhesive bonds that maintain cellular proximity and are 
also a site of intercellular communication. Adherens junctions are composed of 
cadherins, a family of transmembrane proteins that form strong, homotypic interactions 
with molecules on adjacent cells. The cytoplasmic tail of the epithelial cadherin, E-
cadherin (also known as cadherin-1), interacts directly with catenin δ1 (also known as 
p120 catenin) and β-catenin. In turn, β-catenin binds to α-catenin 1, which regulates 
local actin assembly and contributes to development of the peri-junctional ring of actin 
and myosin. Adherens junctions are required for the assembly of tight junctions, which 
in turn are multi-protein complexes composed of transmembrane, scaffolding and 
regulatory molecules that include kinases. Among the transmembrane proteins, claudins 
are the most important and are expressed in a tissue-specific manner. Occludin, another 
transmembrane protein of the tight junction, interacts directly with claudins and actin, 
but its role is less well understood. Amongst peripheral membrane proteins, zonula 
occludens (Zo)1 and Zo2 are crucial for the assembly and maintenance of tight 
junctions, at least in part as they contain multiple domains for the interaction with 
claudins, occludin and actin. Tight junctions limit solute flux along the paracellular 
pathway, which is typically more permeable than the transcellular pathway, therefore 
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they are the principal determinants of transepithelial transport and mucosal permeability 
(Turner, 2009). 
Besides its mechanic action of defence, the epithelium has the important immunologic 
function of transporting immunoglobulin (Ig)A into the lumen using the polymeric Ig 
receptor, and can also produce anti-microbial peptides, cytokines and chemokines in 
response to bacterial and viral invasion. Epithelial cells express a specific class of 
proteins, namely the pattern recognition receptors (PRRs), specialized in the interaction 
with conserved microbial products structures commonly referred to as pathogen-
associated molecular patterns (PAMPs). PRRs comprise a group of transmembrane 
proteins, the toll-like receptors (TLRs), and a class of intracellular proteins, the 
nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs), which play a 
key role in microbial recognition and subsequent induction of anti-microbial genes 
(Medzhitov and Janeway, 2002)  and ultimately in the control of adaptive immune 
responses towards commensal and pathogenic bacteria. In particular, mammalian TLRs 
comprise a family of 11 individual type I transmembrane receptors which are 
characterised by three common structural features: a divergent ligand-binding 
extracellular domain with leucine-rich repeats (LRRs), a short transmembrane region, 
and a highly homologous cytoplasmic Toll/interleukin (IL)-1 receptor (TIR) domain, 
similar to that of the IL-1 receptor family and essential for initiation of downstream 
signalling cascades (Xu et al., 2000). TLRs are differentially (inducibly or 
constitutively) expressed by many distinct cell types throughout the whole GI tract, 
including mature and immature epithelial cells of the stomach, small intestine and 
colon, as well as intestinal lamina propria monocytes/macrophages (Cario et al., 2000), 
dendritic cells (DCs), myofibroblasts, endothelial cells and adipocytes. 
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Several PAMPs selectively activate specific PRRs. TLR2, for example, recognises 
bacterial lipopeptides and lipoteichoic acid, which are found abundantly in the cell wall 
of Gram-positive bacteria. TLR3 is activated by double-stranded RNA. TLR4 is the 
major receptor for lipopolysaccharide (LPS), however the interaction is not direct but 
occurs after the formation of a complex between LPS, serum LPS binding protein 
(LBP) and CD14 on the cell surface, which in turn delivers LPS to MD2 (Akira et al., 
2006). TLR5 recognizes flagellin and flagellated bacteria, TLR7 interacts with 
‘‘antisense’’ single-stranded viruses, TLR9 recognizes methylated CpG-DNA found in 
prokaryotic genomes and DNA viruses, and TLR11 is activated by pathogenic bacteria 
in the urinary tract (Cario, 2005). The NOD family comprises more than 20 different 
mammalian proteins which mostly contain three distinct functional domains: a carboxy-
terminal LRR domain which mediates ligand recognition, a centrally located nucleotide 
binding domain (NBD), and a structurally variable amino-terminal effector-binding 
domain which consists of protein-protein interaction domains, such as caspase 
recruitment domains (CARDs) or pyrin domains (Inohara and Nuñez, 2003). Recent 
research has mostly focused on two cytosolic receptors of this family, NOD1 (also 
designated as CARD4) and NOD2 (also designated as CARD15), which both play a 
major role in intestinal regulation of pro-inflammatory signalling through nuclear factor 
TIR activation in response to distinct bacterial ligands. NOD2 shares significant 
homology with NOD1, but contains two, instead of one CARD domains at its amino-
terminal end. NOD2 has been shown to be constitutively or inducibly expressed in 
monocytes, macrophages, DCs, T cells and B cells (Pauleau and Murray, 2003). It is 
also highly expressed in Paneth cells (Keshav, 2006). 
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TLR signalling is thought to occur through a series of homo- and heterotypic 
interactions between Toll/interleukin (IL)-1 receptor proteins (TIRs) to promote 
oligomerisation with the appropriate TIR-containing adaptor proteins: Myeloid 
differentiation protein 88 (MyD88), MyD88 adaptor-like (Mal), TIR domain-containing 
adaptor inducing interferon- (IFN-) (TRIF), and TRIF-related adaptor molecule 
(TRAM) (Oshiumi et al., 2003). 
 
 After ligand binding, the TLRs dimerize and undergo conformational changes required 
for the recruitment of TIR domain-containing adaptor molecules to the TIR domain of 
the TLR. MyD88 is critical for the signalling of most of the TLRs. Upon stimulation, 
MyD88 associates with the cytoplasmic portion of TLRs and then recruits IL-1R-
associated kinase 4 (IRAK-4) and IRAK-1 through a homophilic interaction of the 
death domains (Figure 1.2) (Li et al., 2002). IRAK-4 then phosphorylates IRAK-1 
which together with tumor necrosis factor (TNF)-α receptor associated factor-6 
(TRAF6), dissociates from the receptor and then TRAF6 interacts with transforming 
growth factor (TGF)-β-activated kinase 1 (TAK1), TAB1, and TAB2. The complex of 
TRAF6, TAK1, TAB1, and TAB2 further forms a larger complex which induces the 
activation of TAK1. Activated TAK1 phosphorylates the IKK complex, consisting of 
IKKα, IKKβ, and NEMO/IKKγ, and MAP kinases, such as JNK, thereby inducing the 
activation of the transcription factors NF-kB and AP-1, respectively  (Takeda and Akira, 
2004). 
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Figure 1.2:TLR4 signaling pathway. In the MyD88 dependent signalling pathway upon TLR4 
stimulation with his ligands MyD88 is recruited and associate with the cytoplasmic portion of 
TLRs and then recruits IRAK-4 which then phosphorylate IRAK-1 and together with tumor 
necrosis factor (TRAF6), dissociates from TRAF6 interacts with TAK1, TAB1, and TAB2. The 
complex of TRAF6, TAK1, TAB1, and TAB2 further forms a larger complex which induces the 
activation of TAK1 which phosphorylates the IKK complex inducing the activation of the 
transcription factors NF-kB and AP-1, respectively resulting in the induction of 
proinflammatory cytokine genes. In the alternatively MyD88 independent TL4 signalling 
pathway, TRIF interacts with RIP1 and TRAF-6 which activate TBK1 that phosphorylate IRF3 
that is responsible for the activation of NF-kB. 
 
 
 
27 
 
 
In the  MyD88-independent TLR4 signalling pathway TRIF interacts with receptor-
interacting protein 1 (RIP1), which is responsible for the activation of NF-kB (Meylan 
et al., 2004). On the other hand, TRIF activates TRAF family-member-associated NF-
B activator (TANK) binding kinase 1 (TBK1; also known as NAK or T2K) via 
TRAF3. TBK1 then phosphorylates IRF3 which translocate into the nucleus, and binds 
to the ISREs, resulting in the expression of a set of IFN-inducible genes (Doyle et al., 
2002; Hoshino et al., 2002). 
 
1.1.2 Macrophages and mononuclear phagocyte system 
Macrophages were first described by Elie Metchnikoff in the 19th century as cells that, 
as part of mammalian immunity, guard the body and ingest and destroy foreign 
material. Macrophages exhibit variable morphology, express non-specific esterase, 
lysosomal hydrolases and ecto-enzymes, and contribute to non-specific uptake of 
particulate material (Hume, 2006). They also express a wide array of receptors for Ig Fc 
and complement components. Macrophages are highly efficient phagocytes, and play a 
central role in the maintenance of tissue homeostasis and wound healing through the 
clearance of apoptotic, senescent and damaged cells. The capability to scavenge dying 
material enables macrophages to play an important role also during organogenesis in 
embryonic development (Hopkinson-Woolley et al., 1994). Macrophages also have 
tissue-specific functions. For example in the liver, macrophages called Kupffer cells are 
present in the lumen of hepatic sinusoids and exhibit endocytic activity against blood-
borne materials entering the liver (Naito et al., 2004).  In the lungs, during the resolution 
phase of tissue damage, alveolar macrophages are initiators of parenchymal repair 
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mechanisms essential for return to homeostasis for normal gas exchange. Osteoclasts, 
the macrophages present in the bones, are essential for bone remodelling. 
 
Macrophages are central members of the innate immune system and, together with 
neutrophils, eosinophils and natural killer cells, function as a first-line defence to 
recognize, eliminate or contain invading microbes and toxic macromolecules. 
Moreover, macrophages play an essential role in the maintenance of immune 
homeostasis by producing immunoregulatory cytokines such as IL-10 and TGF-β 
(Harrison and Maloy, 2011). Macrophage responses towards pathogens and microbes 
are triggered by PAMPs and are rapid. Moreover, when the innate immune system is 
unable to handle and eliminate an invading micro-organism, macrophages serve as 
effector cells of the adaptive immune system, after receiving the appropriate activation 
and information from antigen-specific T cells and B cells. 
 
1.1.3 Origin of monocytes/macrophages 
Tissue macrophages derive from bone marrow stem cells through a complex cascade of 
differentiation events that require the presence of IL-1, IL-3, and IL-6 (Ogawa, 1993). 
These cytokines give rise to a pluripotent myeloid cell type, referred to as granulocyte-
erythrocyte-megakaryocyte-macrophage colony-forming unit (GEMM-CFU). The 
continued presence of IL-1 and IL-3 induces the GEMM-CFU to become progenitors of 
both macrophages and granulocytes known as granulocyte-macrophage colony-forming 
unit cells (GM-CFU) (Lopez et al., 1992). At this point, IL-3 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) induce the proliferation of myeloid 
precursors, whereas macrophage colony-stimulating factor (M-CSF) induces not only 
their proliferation but also their differentiation to the monocyte precursor (M-CFU). The 
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persistent presence of IL-3, M-CSF and GM-CSF leads to the differentiation of the 
monoblast, then to the promonocyte, which shows a limited phagocytic capability 
(Figure 1.3). Promonocyte differentiation into monocytes requires the presence of M-
CSF. Monocytes are generally smaller than their immediate precursors, but they have a 
well-developed lysosomal system and enhanced phagocytic capability (Hamilton, 
1993). 
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Figure 1.3: Differentiation of stem cells to monocyte/macrophages: Pluripotent stem cells 
differentiate into myeloid progenitors in the bone marrow where, under the influence of growth 
and colony stimulating factors, the cells differentiate into monoblasts. Monoblasts in turn 
develop into monocytes and migrate from the bone marrow into the blood where they circulate 
for several days and then are distributed to the tissues either as resident macrophages or as 
recruited macrophages at sites of infection and inflammation.  
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After leaving the bone marrow, monocytes enter the blood and are subsequently 
distributed to the various tissues either as resident macrophages or as recruited 
macrophages at the sites of infection and inflammation. The maturation of macrophages 
involves an increase in size and an increase in the lysosomal content and amount of 
hydrolytic enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
1.2 Intestinal macrophages 
1.2.1 Introduction 
Intestinal macrophages represent the most abundant subpopulation of mononuclear 
phagocytes in the body and are usually localized in the lamina propria, underneath the 
superficial small blood vessels just below the sub-epithelial collagen layer, and in the 
muscularis propria, which faces the peritoneum. This strategic localization guarantees a 
first-line defence against  the huge numbers of potentially harmful bacteria and 
antigenic stimuli that are present in the intestinal lumen (Sagaert et al., 2012).  
 
1.2.2 Recruitment of blood monocytes to the gut 
Little is known about the mechanisms regulating the recruitment of circulating 
monocytes and their differentiation into resident macrophages within the intestinal 
lamina propria. Among the many hypothesis, intestinal inflammatory macrophages 
develop from CD14
+
CD16+ monocytes and resident macrophages from CD14
+
CD16
-
 
monocytes  (Fiocchi, 2008). Compared with CD14
+
CD16
+ 
monocytes (which are also 
CD64
+
), CD14
+
CD16
- 
monocytes have a high phagocytic activity and produce large 
amounts of cytokines such as TNF- and IL-6, and these features are  not shared with 
the CD14
+
CD16
+
CD64
–
 subset (Gordon and Taylor, 2005). It has been assumed that 
intestinal macrophages display functional plasticity under different conditions, an idea 
consistent with the paradigm that there are “resident” and “inflammatory” lineages of 
monocytes (Geissmann et al., 2010a). 
 
Circulating blood monocytes then, under the influence of TGF- and IL-8, are recruited 
into the lamina propria (Smythies et al., 2006), where during homeostasis they 
differentiate preferentially into inflammation-anergic intestinal macrophages (Smith et 
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al., 2011). This  process is driven by TGF- thereby down-regulating the subsequent 
production of pro-inflammatory cytokines (Smythies et al., 2010). 
Other mechanisms apart from TGF- and IL-8 have been reported to regulate monocyte 
migration to the lamina propria; after circulating in the bloodstream, monocytes 
extravasate into tissues using adhesion molecules such as L-selectin (CD62L), P-
selectin glycoprotein ligand 1 (PSGL1), lymphocyte function-associated antigen 1 
(LFA1) and platelet endothelial cell adhesion molecule (PECAM1) (Ley et al., 2007); 
(Shi et al., 2011), together with chemotactic factors such as CSF1 and the chemokines 
CX3CL1 and CXCL12. Once in tissues, monocytes differentiate into macrophages 
under control of CSF1 (Auffray et al., 2009); (Fong et al., 1998); (Pixley and Stanley, 
2004). Amongst the chemokine receptors, it has been previously reported that CCR2 
(CCL2 receptor) plays a key role in monocyte recruitment to the gut during 
inflammation. The best known role for CCR2 is in the accumulation of the Ly6Chi 
subset of monocytes at sites of inflammation. Moreover as noted above, the idea that 
CCR2 dependent accumulation of monocytes is only important in intestinal 
inflammation has been challenged by the recent work which indicates that CCR2
+
 
Ly6C
hi
 monocytes appear to replenish steady state intestinal macrophages (Bain et al., 
2013). This is supported a work showing that the accumulation of IL10 producing 
intestinal macrophages in normal intestine is dependent on CCR2 and its ligand CCL2 
(Feterowski et al., 2004). Moreover it has also been suggested that CCR2 dependent 
monocytes actually play a protective role in the intestinal inflammation associated with 
T. gondii infection, by encouraging tissue repair and inhibiting pathogenic neutrophil 
activity (Grainger et al., 2013). Finally other receptors such as CCR1 and CCR5 have 
been implicated in monocyte recruitment (Lebre et al., 2011; Tokuyama et al., 2005). 
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Marker Intestinal macrophages Inflammatory macrophages Monocyte
CD11b +++ +++ +++
F4/80 +++ ++ +/-
CD68 ++ ++ -
Class II MHC +++ ++/+ -
CD11c ++ ++ -
CX3CR1 +++ ++ -
CCR2 ++ +++ ++/-
CD40 +/- +/- -
CD80,CD86 +/- +/-
CD14 + ++ +++
TLR2 ++ ++ +++
TLR4 +/- + +++
Mannose R ? ? -
Scavenger R ? ? -
Phegocytosis +++ +++ +
iNOS - ++ +
ROI - ++ +
TNF- ± +++ +
IL-10 ++ ± -
Arginase - -/++ -
COX-2 ++ ? -
IL-4R - - -
IL-10R + - -
CD33 ++ +++ +  
Table 1.1: Receptor expression on intestinal macrophages, inflammatory macrophages 
and monocytes. Resident mucosal macrophages in resting colon are compared with recruited 
macrophages which infiltrate during intestinal inflammation in IBD and blood monocytes. 
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Lamina propria macrophages are phenotypically distinct both from blood monocytes 
and from other tissue macrophages (Table 1.1). While tissue macrophages, such as 
Kupffer cells and alveolar macrophages, are able to proliferate locally (Tarling et al., 
1987), it has been shown that gut lamina propria macrophages are unable to replicate, 
which suggests that intestinal macrophages are replenished solely by blood monocytes. 
Moreover, resident macrophages of the gut display an inflammation-anergic phenotype 
(Sagaert et al., 2012) with little or no expression of various PRRs, including CD14,  
CR3 component (CD11b/CD18), Ig receptors CD16 and CD32  (Smythies et al., 2005). 
Normal intestinal macrophages also lack receptors for IL-2 and IL-3, as well as the 
chemokine receptors CCR5 and CXCR4, the integrin leukocyte function-associated 
antigen (LFA)-1 (Platt and Mowat, 2008) and the triggering receptor expressed on 
myeloid cells (TREM)-1, an efficient amplifier of acute and chronic inflammatory 
reactions expressed on most monocytes and macrophages in secondary lymphoid 
organs. The lack of expression of IgA receptor (CD89) and the low expression of CD14 
prevent resident macrophages from participating to the inflammatory cascade and 
thereby promote the maintenance of homeostasis present at the steady state in the 
intestinal mucosa (Smith et al., 2005). 
Intestinal lamina propria macrophages, under physiological conditions, are not only 
refractory to the induction of pro-inflammatory cytokine production by PAMPs but  
also by other pro-inflammatory cytokines (e.g. TNF-, IFN-γ), or upon phagocytosis of 
necrotic cells (Smith et al., 2005). This is in sharp contrast to most other tissue 
macrophages and blood monocytes. 
 
However, intestinal macrophages retain their phagocytic activity, which is remarkably 
powerful. Compared to circulating monocytes, intestinal macrophages are highly 
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effective at killing phagocytosed microorganisms such as  S. typhimurium and E. coli 
(Smythies et al., 2005). Phagocytosis of apoptotic cells by intestinal macrophages also 
induces the secretion of immunosuppressive cytokines such as IL-10 and TGF-β, 
whereas the secretion of pro-inflammatory cytokines such as TNF-, IL-12, IL-6 and 
IL-1β is significantly inhibited (Qualls et al., 2006). Moreover, intestinal macrophages 
in homeostatic conditions continuously act as sentinel phagocytic cells, continuously 
sampling and surveying the commensal microbiota (Mowat and Bain, 2011).  
 
1.2.3 Classical macrophage activation 
Intestinal macrophages have the ability to change from one phenotype to another. The 
activation of macrophages in response to pathogenic stimuli has been termed “classical 
activation”, resulting in macrophages identified as classically activated macrophages or 
M1 (Lin et al., 2006). Classical macrophage activation results from the recognition of 
PAMPs on the surface of Gram-positive and Gram-negative bacteria. Macrophages 
express a range of TLRs and other PRRs which are triggered during phagocytosis of 
pathogenic material. Classical activation of macrophages is dependent on the activation 
of signal transducer and activator of transcription (STAT)1 and interferon regulatory 
factor (IRF)5 (Krausgruber et al., 2011). This results in the production of pro-
inflammatory cytokines, including TNF-, IL-1β, IL-6, IL-12 and IL-23, and 
chemokines such as the Chemokine (C-X-C motif) ligand 9 (CXCL9)  and C-X-C motif 
chemokine 10 (CXCL10) (Mosser and Edwards, 2008). The activation of TLR4 is one 
of the main pathways responsible for the production of pro-inflammatory cytokines, 
chemokines, adhesion molecules such as intracellular vascular adhesion molecule-1 and 
intracellular-1 adhesion molecule, and overexpression of co-stimulatory molecules such 
as CD80 and CD86 (Takeda and Akira, 2005). Pro-inflammatory mediators released by 
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classically activated macrophages facilitate the recruitment of other inflammatory 
leukocytes such as monocytes and neutrophils, as well as the polarisation of T 
lymphocytes to the pro-inflammatory T helper (Th)1 and/or Th17 phenotypes. As 
showed in Figure 1.4, classically activated macrophages also express inducible nitric 
oxide synthase (iNOS or NOS2), allowing them to generate nitric oxide (NO) from L-
arginine. M1 macrophages also produce other cytotoxic mediators such as superoxide 
anions and other oxygen radicals through expression of the enzyme nicotinamide 
adenine dinucleotide phosphate-oxidase (NADPH).   
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Figure 1.4: Macrophages activation: Cytokines produced by immune cells can give rise 
macrophages with distinct phenotypic and functional properties defined as classically activated, 
alternatively activated and regulatory macrophages. 
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Furthermore, their ability to up-regulate the expression of the major histocompatibility 
complex class II (MHC) and co-stimulatory molecules allows classically activated 
macrophages to act as antigen presenting cells (APC) for T cells. However, these potent 
pro-inflammatory properties also mean that classically activated macrophages must be 
tightly controlled, as aberrant or excessive activity can lead to tissue damage. Indeed, 
macrophages exhibiting M1 characteristics are commonly found in excess at the sites of 
chronic inflammation (Abraham and Medzhitov, 2011). 
 
 1.2.4 Alternative macrophage activation  
Although in the past, the main feature of alternatively activated macrophages was 
considered to be the ability to inhibit classical macrophage activation (Ohmori and 
Hamilton, 1997), it now has become clear that alternatively wound-healing macrophages 
are involved in the tissue repair. Macrophages are polarised to M2 phenotype by Th2 
cells. IL-4 and IL-13 are the prototypical direct inducers but other cytokines such as IL-
33 and IL-25 amplify M2 induction indirectly, through Th2 cells (O'Shea and Paul, 
2010). Th2 cells, macrophages, and B cells, as well as tumor cells, are potent down-
regulators of macrophage gene expression, a process controlled by IRF4, STAT6 and 
the peroxisome proliferator-activated receptor gamma (PPARγ) (Satoh et al., 2010). M2 
macrophages do not express pro-inflammatory cytokines and iNOS and are poor 
producers of reactive oxygen and nitrogen species. In contrast, they express the 
mannose receptor (CD206), FIZZ1, Ym1, and produce chemokines such as CCL22 
(MDC), which attract CCR4
+
 CD4
+ 
Th2 cells (Bonecchi et al., 1998). Ym1 belong to a 
family of chitinase-like molecules which are strongly induced by Th2 cell stimuli on 
macrophages as well as epithelium. Fizz1, is a secreted protein produced by 
macrophages, epithelium, and eosinophils, and it is highly induced by IL-13. Fizz1 in 
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lung allergy and asthma may inhibit inflammation (Nair et al., 2009). Fizz 
-/-
 M2 
macrophages display an exaggerated ability to drive antigen-specific Th2 cell 
differentiation. Fizz1 protein binds to macrophages and effector CD4
+
 Th2 cells, 
inhibiting Th2 cytokine production. For example, NO generated by IFN-γ-induced 
iNOS is shut down in macrophages (it is induced in epithelial targets), with a shift to 
Arginase-1 (Arg1) considered to have a possible role in switching to an alternative 
versus classical activation. Interactions with mast cells, basophils, eosinophils, and 
NKT cells, as well as IgE and selected subclasses of IgG, promote allergy and 
hypersensitivity. Together they influence vascular permeability, angiogenesis, cell 
recruitment, smooth muscle contraction, goblet cell secretion, mucus production, and 
collagen deposition by myofibroblasts (Locksley, 2010). They also express Arg1 (Loke 
et al., 2002), allowing them to convert L-arginine to L-ornithine, which is a precursor of 
polyamines and collagen, and facilitates tissue remodelling and encapsulation of 
helminths (Gordon and Martinez, 2010).  
 
1.2.5 Regulatory macrophage activation 
Similarly to the two populations above, a third population of macrophages, which exert 
marked effects during stress, can arise following innate or adaptive immune responses. 
Although stress responses are not typically considered part of innate immunity, when 
glucocorticoids are released by adrenal cells in response to stress, they can inhibit 
macrophage mediated host defence and inflammatory functions by inhibiting the 
transcription of pro-inflammatory cytokine genes and decreasing mRNA stability, 
giving rise to a population of regulatory macrophages (Sternberg, 2006). Regulatory 
macrophages can also arise during the later stages of adaptive immune responses, the 
primary role of which seems to be to dampen the immune response and limit 
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inflammation (Mosser, 2003). There are many different ways to generate regulatory 
macrophages in vitro, for example  stimulation  with TLRs agonists in the presence of 
IgG immune complexes promotes the development of a population of regulatory 
macrophages that produce high levels of IL-10 (Gerber and Mosser, 2001). Regulatory 
macrophages may also be activated by adenosine (Haskó et al., 2007), dopamine, 
histamine, sphingosine 1-phosphate, melanocortin, vasoactive intestinal peptide, 
adiponectin and Siglec-9 (Huang et al., 2008). Because IL-10 can inhibit the production 
and activity of various pro-inflammatory cytokines, these regulatory macrophages are 
potent inhibitors of inflammation, despite the fact that they retain the ability to produce 
many pro-inflammatory cytokines. Unlike wound-healing macrophages, regulatory 
macrophages do not contribute to the production of the extracellular matrix, and many 
of these regulatory cells express high levels of co-stimulatory molecules (CD80 and 
CD86) and therefore can present antigens to T cells (Edwards et al., 2006). 
 
1.2.6 Endotoxin tolerance 
Prolonged or excessive macrophage activation can be deleterious to the host due to the 
potential for macrophages to cause pathology. Therefore, multiple mechanisms exist to 
ensure that macrophage activity is appropriately regulated. One of the most effective 
protective mechanisms that suppress inflammatory cytokine production by macrophages 
is endotoxin tolerance. Monocytes and macrophages are the principal cells involved in 
endotoxin tolerance in vivo, and tolerization of these cells has been studied extensively 
(Biswas and Mantovani, 2010). Endotoxin tolerance selectively prevents inflammation 
associated with excessive cytokine production while allowing beneficial TLR-induced 
responses, such as the production of anti-microbial peptides. Endotoxin tolerance is 
accompanied by the down-regulation of TLR4 (Nomura et al., 2000), decreased 
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association of TLR4 with MyD88 adaptor protein, and decreased association of MyD88 
with IRAK (Medvedev et al., 2002). Besides promoting MyD88 activation, LPS 
stimulation is known to cause the induction of splice variants of the MyD88 protein that 
lack the necessary domain to interact with IRAK4, thereby inhibiting positive TLR 
signalling (Burns et al., 2003). Moreover, TLR activation induces the activation of 
IRAK-M, a molecule that inhibits the dissociation of IRAK1-IRAK4 from the TLR 
signalling complex, by inhibiting their phosphorylation and thereby preventing further 
signalling. IRAK-M expression is restricted by macrophages and monocytes and its 
levels are increased when cells are stimulated with LPS (Kobayashi et al., 2002). Toll-
interacting protein (Tollip) represents another adaptor protein which maintains immune 
cells in a quiescent state in the absence of infection. Tollip was found to associate with 
the cytoplasmic TIR domain of IL-1 receptors (IL-1Rs) after IL-1 stimulation. Within 
resting cells Tollip forms a complex with IRAK and inhibits IL-1-induced signalling by 
blocking IRAK phosphorylation (Burns et al., 2000). Because of the significant 
homology in the intracellular portion of TLRs, IL-1R, and IL-18R, Tollip might also 
inhibit TLR-mediated signalling by interacting with TLRs through the TIR domain 
(Zhang and Mosser, 2008). Suppressor of cytokine signalling (SOCS)-1 was discovered 
independently on the basis of its ability to interact with the kinase domain of Janus 
kinase (JAK)2 and was named JAK-binding protein (JAB) (Endo et al., 1997). It was 
also discovered because of similarity of the SOCS-1 SH2 domain to a sequence motif in 
the STAT3 SH2 domain, and was referred to as STAT-induced STAT inhibitor (SSI)-1 
(Narazaki et al., 1998) . Transcription of the SOCS-1 gene is induced in response to a 
number of cytokines, such as IL-6, IL-4 and IFN-γ, and the protein has been shown to 
inhibit the tyrosine phosphorylation of each member of the JAK family of protein 
tyrosine kinases (Nicholson et al., 1999). 
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1.3 Induction of adaptive immune responses in the gut 
The gut-associated lymphoid tissue (GALT) can be classified into effector sites, which 
consist of lymphocytes scattered along the epithelium and lamina propria of the mucosa, 
and organized structures that are responsible for the induction of the immune response 
(Mowat, 2003). Primary sites for the induction of immunological responses are small 
intestinal Peyer's patches, which consist of a collection of large B cell follicles and T 
cell areas, isolated lymphoid follicles (ILFs) in the small and large intestine, and MLNs 
(Kraehenbuhl and Neutra, 2000). 
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Figure 1.5: Schematic representation of the lymphoid elements of the intestinal immune 
system. Antigen might enter through the microfold (M) cells in the follicle-associated 
epithelium (FAE) (a), and after transfer to local DCs, might then be presented directly to T cells 
in the Peyer’s patch (b). Alternatively, antigen or antigen-loaded DCs from the Peyer’s patch 
might gain access to draining lymph (c), with subsequent T-cell recognition in the MLNs. 
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The organized gut lymphoid structures are separated from the intestinal lumen by a 
single layer of columnar epithelial cells, also known as follicle-associated epithelium 
(FAE) (figure 1.5), and by a more diffuse area below the epithelium known as the 
subepithelial dome (SED). The most notable feature of the FAE is the presence of 
microfold (M) cells, which are specialized antigen-transporting enterocytes lacking 
surface microvilli (Debard et al., 2001) (Golovkina et al., 1999). M cells provide the 
main way in which complex antigens can gain access to the intestinal immune system. 
M cells do not express MHC class II molecules and do not process antigens  (Mantis et 
al., 2002), however they are believed to be essential in passing on intact antigens to 
professional APCs, either in the epithelium or in the underlying SED. APCs 
subsequently move to the T cell areas and/or B cell follicles in the Peyer’s patches, 
where they can interact with naïve lymphocytes (Salzman et al., 2007). Following the 
interaction with the antigens the lymphocytes primed in the Peyer’s patches migrate 
through the draining lymphatic vessels to the MLNs, where they reside for an undefined 
period of further differentiation, before further migrating into the bloodstream from 
where they are recruited and redistributed to the effector sites of the intestinal mucosa. 
The efficient homing and retention of lymphocytes to the gut is dependent on the β7-
containing integrins, α4β7 and αEβ7 integrin in presence of retinoic acid, made by DCs, 
as well as the chemokine CCL25 and its receptor CCR9 (Salmi and Jalkanen, 2005). 
α4β7 integrin binds Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), 
which is constitutively expressed on high endothelial venules (HEVs) of PPs and MLNs 
as well as on postcapillary venules of gut LP. Both naïve and effector lymphocytes use 
α4β7 integrin to extravasate from blood to gut mucosal tissues of GALT, MLN and 
lamina propria via interactions with MAdCAM-1. 
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Next, lymphocytes entering the mucosa are redistributed to distinct compartments. B-
cell blasts mature into IgA-producing plasma cells and remain in the lamina propria. 
CD4
+
 T cells also remain in the lamina propria, but are distributed more evenly 
throughout the villus-crypt unit. CD8
+
 T cells migrate preferentially to the epithelium, 
although ~40% of T cells in the lamina propria are also CD8
+
, where they can have 
potent cytotoxic activity (Lefrançois et al., 1999). Some of these antigen-experienced 
lamina propria T cells may be true effector cells, and may help local B cells to produce 
IgA. Alternatively, they may be ‘effector memory’ cells (Sallusto et al., 1999), as 
indicated by the observations that antigen-specific memory CD4
+
 and CD8
+
 T cells 
accumulate preferentially in non-lymphoid tissues, in particular in the intestinal mucosa 
(Reinhardt et al., 2001). CD4
+
 T cells in the lamina propria are particularly important in 
local immune regulation. They produce large amounts of pro-inflammatory and 
regulatory cytokines, particularly IFN-γ, but also IL-4 and IL-10. Due to the presence of 
such a vast range of immune cells under normal conditions, the intestine has been often 
described as being in a state of physiological inflammation, emphasising the delicate 
balance needed to maintain homeostasis. 
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1.4 Mechanisms of immune tolerance in gut 
The mucosa of the small and large intestine is constantly exposed to a large variety of 
TLR ligands, to a great antigenic load from luminal bacteria, and to potential mitogens. 
Many pathways and cell types are implicated in the regulation of host-environment 
interaction and in the generation and maintenance of immune tolerance in the GI tract, 
including inhibitory macrophages and DCs, regulatory T cells (Tregs), T cell apoptosis, 
and immunoregulatory cytokines (Macpherson et al., 2008) (Rescigno et al., 2001). The 
exact mechanisms that support the maintenance of oral tolerance remain to be 
established with certainty, but anergy of reactive T cells may be involved. CD4
+
 Tregs 
expressing the transcription factor forkhead box P3 (Foxp3) are present at higher 
frequencies in the gut lamina propria, particularly in the colon, than in other organs 
(Hall et al., 2008). It has been postulated that Foxp3
+
 Tregs are induced by luminal 
antigens and prevent antigen-specific responses through cell-cell interactions and 
regulatory cytokine production. Furthermore, colonization of mice with human 
commensal Bacteroides fragilis facilitates Treg differentiation and IL-10 production 
(Round and Mazmanian, 2010). Atarashi and colleagues showed that mice inoculated 
with chloroform-treated feces displayed an increased number of Tregs , comparable to 
that in germ-free mice gavaged with untreated feces. Clostridia species were shown as  
having the most important role in the induction of colonic Tregs by activating TGF-β 
and by inducing the production of other Treg-inducing factors from intestinal epithelial 
cells, which presumably cooperate with DCs to induce a general accumulation of Tregs 
in the colon and at the same time affect the proportions of individual Treg subsets 
through the preferential induction of IL-10
+ 
inducible Tregs (Atarashi et al., 2011). 
More recently, the same group identified Treg-cell-inducing bacterial strains derived 
from the human microbiota. Stool samples from a healthy Japanese volunteer were 
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untreated or treated with chloroform and orally inoculated into IQI/Jic germ-free mice, 
in which they induced a significant increase in the percentage of Foxp3
+
 Treg cells 
among CD4
+
 T cells in the colon. These findings suggested that the human intestinal 
microbiota contains Treg-cell-inducing bacteria (Atarashi et al., 2013). 
 
Within the gut mucosa, not only the Tregs but several other cell types, including 
macrophages and myofibroblasts, can produce and respond to TGF-β. However a major 
source of TGF- is mainly produced from epithelial cells in a latent complex formed by 
three proteins: TGF-, the processed TGF- propeptide, and a member of the latent 
TGF- binding protein (LTBP) family and is activated by an epithelium-restricted 
integrin v6 (Munger and Sheppard, 2011). In the gut TGF-β and IL-8 act as 
chemokines on circulating blood monocytes by inducing the recruitment of blood 
monocytes in the lamina propria where, like described above, during homeostasis they 
differentiate preferentially into inflammation-anergic intestinal macrophages (Smith et 
al., 2011). This process is driven by TGF-β, which prevents the translocation of  NF-B 
into the nucleus and, therefore, down-regulates  the subsequent production of pro-
inflammatory cytokines (Smythies et al., 2010).  
TGF-β blocks NF-B activation in macrophages in response to TLR2, TLR4 and TLR5 
stimulation also by facilitating the proteasomal degradation of MyD88 (Naiki et al., 
2005). As a result, a breach in epithelial integrity normally triggers host  defence 
activity (Maheshwari et al., 2011) but not an inflammatory response by macrophages in 
the gut  (Smythies et al., 2006). 
Epithelial cells play an important role in the activation and communication with the 
cells underlying; the interaction of macrophages and DCs with the epithelial cells is 
thought to be integral for the conditioning of the immune cells to their local 
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environment. The first evidence for this came from co-colture studies with epithelial 
cells and human monocyte derived DCs, whereby epithelial cells treated with different 
bacterial strain produced different pro-inflammatory mediators which modulated DCs 
function (Rimoldi et al., 2005).  
In addition to TGF- and prostaglandin E2, also thymic stromal lymphopoietin (TSLP) 
production by epithelial cells contribute to the ability of these cells to condition DC to 
express pro-inflammatory cytokines subsequently affecting their ability to induce naïve 
T cell polarization. TSLP although constitutively expressed can be up-regulated in 
response to infection, inflammation and tissue injury (Allakhverdi et al., 2007; Bogiatzi 
et al., 2007; Kato et al., 2007). Consistent with the role of TSLP in the skin and lung, 
epithelial cells-derived TSLP has been show to condition DCs to drive Th2-like anti-
inflammatory T cell differentiation, while limiting their production of IL-12 (Rimoldi et 
al., 2005). 
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1.5 Inflammatory bowel disease  
1.5.1 Introduction 
The inflammatory bowel diseases are a group of chronic and relapsing inflammatory 
conditions of the gastrointestinal tract, believed to be caused by a complex interplay 
between genetic, immunologic, microbial and environmental factors. In particular, IBD 
is thought to be driven by an inappropriate immune response directed against the enteric 
microbiota in a genetically susceptible host. The two major forms of IBD are Crohn’s 
disease (CD) and ulcerative colitis (UC). CD can affect the whole gastrointestinal tract 
but is mainly localised to the colon and terminal ileum, whereas UC exclusively affects 
the colon (Blumberg, 2009). Both forms of IBD are characterised by a substantial 
infiltrate of neutrophils, monocytes, macrophages, eosinophils and T cells into the 
intestinal wall. The inflammatory infiltrate in CD is mostly mononuclear with 
granulomata, hallmarks of classical cell-mediated immunity.  CD is characterised by a 
predominant Th1 mucosal cytokine profile with elevated levels of IFN-γ, IL-2, IL-12 
and TNF-α (Macdonald, 2010). It has been suggested that UC is driven by an atypical 
Th2 response, with IL-5 and IL-13 being produced by NK T cells (Kaser et al., 2010). 
However studies from our lab failed to find increased IL-13 in UC (Biancheri et al., 
2013a). The failure of anti-IL-13 in 2 recent trials of patients with UC reinforces the 
notion that the atypical Th2 response is incorrect (Tilg and Kaser, 2015). 
 In the last few years, other factors have been recognised to contribute to the 
pathogenesis of IBD, and the paradigms formulated some years ago to explain the 
mechanisms underlying these conditions have undergone a rapid and, in some cases, 
radical change in the light of more recent knowledge. The Th1/Th2 paradigm has in fact 
been replaced by the Th1/Th17 paradigm since high levels of IL-17A are present in both 
UC and CD inflamed mucosa. In order to determine whether a particular cytokine is 
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important in IBD it is critical to take into account the data on the effect of its in vivo 
neutralisation in humans. Anti-TNF- therapies are a clear example of the relevance of 
this approach. In fact, infliximab induces clinical improvement and clinical remission in 
80% and 50% of CD patients, respectively, thus proving the importance of TNF- in 
CD. However, blocking IFN-γ, IL-17A, CD80/B7-1 and IL-12/23 have all failed in 
clinical trials in unselected patients with CD (Biancheri et al., 2013b). 
 
  1.5.2 TLRs in IBD 
The role and influence of TLRs in the pathogenesis of IBD has become increasingly 
evident and widely acknowledged (Atreya et al., 2011). Among the TLRs, TLR2, 
TLR4, TLR5 and TLR9 have been shown to have important role in intestinal 
inflammation. Mice deficient in TLR2, TLR4 or TLR9 have increased susceptibility to 
both 2,4,6-trinitrobenzene sulfonic acid (TNBS)- and dextran sulfate sodium (DSS)-
induced murine colitis (Kopprasch et al., 2002). TLR2 appears to play an essential pro-
inflammatory role in the pathogenesis of IBD. Indeed, Hausmann et al. observed a 
marked increase in TLR2 expression on mucosal and submucosal CD68
+
 intestinal 
macrophages from inflamed areas of IBD patients in comparison to those of control 
subjects, which instead exhibited little to no expression of TLR2  (Hausmann et al., 
2002). Interestingly, TLR2 was highly expressed compared to control subjects in 
colonic biopsies taken from both children with newly diagnosed IBD and from patients 
with long-standing disease (Szebeni et al., 2008). A novel study by Canto et al. 
demonstrated that colonic lamina propria monocytes from active IBD patients exhibit 
high levels of TLR2 on their cell surface, and that TLR2 stimulation on their surface 
induced markedly high levels of TNF-α production in comparison to monocytes from 
inactive IBD patients and control subjects (Cantó et al., 2006). TLR4 has also been 
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implicated in the pathogenesis of IBD. Both TLR4 and MyD88 knock-out mice display 
significantly impaired intestinal barrier function and show defective mucosal healing in 
DSS-induced colitis. Moreover,  mucosal TLR4 expression is markedly up-regulated in 
both CD and UC patients compared to normal subjects (Levin and Shibolet, 2008). 
Despite some conflicting evidence, TLR5 is generally believed to contribute to the 
pathogenesis of IBD (Lodes et al., 2004). One study has reported that intra-rectal 
administration of flagellin directly into DSS-treated mice greatly enhanced colitis 
symptoms relative to control mice (Levin and Shibolet, 2008). Accordingly, TLR5 
knock-out mice develop spontaneous colitis and display markedly higher mucosal pro-
inflammatory cytokine production (Vijay-Kumar et al., 2007). Furthermore, sera from a 
substantial proportion of CD patients contains a marked elevation of anti-flagellin 
antibodies relative to healthy control subjects (Heinsbroek and Gordon, 2009). Also 
TLR9 seems to be involved in intestinal inflammation. In particular, some studies 
revealed that the apparent success of treating colitic mice with bacterial probiotics was 
in part, facilitated via CpG activated TLR 9 signalling  (Pedersen et al., 2005). However 
in CD, probiotics have been completely ineffective in either inducing or maintaining 
remission. The effects of CpG oligo-deoxynucleotides able to stimulate TLR9 were 
investigated on colonic mucosal biopsies from active UC patients (Hornung et al., 
2002). CpG significantly reduced colonic expression of IL-1 and TNF-α by UC 
colonic biopsies cultured ex vivo, with a mechanism dependent on TLR9 (Lodes et al., 
2004). 
 
1.5.3 Intestinal macrophages in IBD  
The anergic phenotype of intestinal macrophages represent the principal mechanisms 
that  prevent the inappropriate reactions to  commensal microbes that cause IBD (Bain 
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and Mowat, 2011). However, resident mucosal macrophages may fail in maintaining the 
anergic phenotype and can produce pro-inflammatory mediators in response to stimuli 
such as the TLRs (Geissmann et al., 2010b). More specifically, the release of these pro-
inflammatory cytokines induces epithelial cell apoptosis, lesions in the mucosal barrier, 
compromises the integrity and permeability of the barrier, and promotes necrosis, 
fibrosis, and the formation of granuloma (Goto and Kiyono, 2012) 
 
Both in experimental colitis and in human IBD, activated macrophages play an 
important role in the initiation of the inflammatory process (Strauss-Ayali et al., 2007). 
In patients with active IBD macrophage numbers are increased and many of these 
macrophages display a different phenotypic and functional profile than under 
homeostatic conditions. Macrophages in the inflamed intestine express functional T cell 
co-stimulatory molecules such as CD40, CD80 and CD86, and they also express TLR2, 
TLR4, CD89 and TREM-1 at the site of intestinal inflammation. Similarly, a high 
proportion of the macrophages from patients with IBD express CD14 (Kamada et al., 
2008; Smith et al., 2001). CD14-expressing macrophages infiltrating the mucosa in IBD 
promote the recruitment of other effector cells producing inflammatory mediators such 
as  TNF-α, IL-1, IL-6 and NO (MacDonald et al., 2011).  They also produce large 
amounts of IL-12, IL-23 and IFN-γ (Kamada et al., 2008). Moreover, the production of 
TNF-α and other mediators by these macrophage population plays a crucial role in the 
tissue damage (Mowat, 2003).  
CD14
+
 intestinal macrophages from CD patients respond vigorously to in vitro 
microbial stimulation by producing even more TNF-, IL-12 and IL-23 compared to 
CD14
- 
 intestinal macrophages and peripheral blood mononuclear cells (PBMCs) 
(Kamada et al., 2008). 
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1.5.4 The role of TNF- in IBD 
Human TNF-α is a member of a large family of proteins and receptors which are 
critically involved in immune regulation (MacDonald et al., 2011). TNF- exists in two 
forms: membrane-bound (m)TNF- and a soluble form (sTNF-) (Kollias et al., 1999). 
Upon stimulation by for example  LPS, newly synthesized TNF rapidly accumulates in 
the Golgi complex as a type II transmembrane protein (Shurety et al., 2000) and the 
molecule is then transported to recycling endosomes before delivery to the plasma 
membrane (Murray et al., 2005). Upon further stimulation membrane TNF can be 
cleaved by a metalloprotease domain 17 (ADAM17) between residues Ala76 and Val77 
(Gearing et al., 1994). Soluble TNF is released from the cell surface as a homotrimer in 
the form of three mature 17 kDa TNF molecules (Black et al., 1997). 
Soluble TNF- can signal through  type 1 and 2 TNF receptors (TNFR1 and TNFR2), 
which are expressed as pre-assembled trimers on the cell surface (Chan et al., 2000). 
While TNFR1 is present in all nucleated cells, TNFR2 is found solely on immune cells, 
endothelial cells and neurons (Hodgkinson et al., 2008).  
These receptors can act as ligands or signalling molecules. TNFR1 is capable of directly 
inducing apoptosis through its death domain (DD) (Nakao et al., 2005). TNFR2 does 
not contain a DD and can be fully stimulated only by the membrane integrated form of 
the ligand (Grell et al., 1995). Upon stimulation by soluble TNF, TNFR2 is thought to 
be a ligand passing receptor that after capturing soluble TNF, rapidly transfers the 
molecule to TNFR1 (Tartaglia et al., 1993). 
Upon contact with their ligand TNFR1 undergo to a conformational change, thus 
leading to the dissociation of the inhibitory protein silencer of death domains (SODD) 
from the intracellular death domain. The dissociation enables the adaptor protein tumor 
necrosis factor receptor 1-associated death domain protein (TRADD) to bind to the 
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death domain, serving as a platform for subsequent protein binding (figure 1.6). 
TRADD then recruits TRAF2 and RIP. TRAF2 in turn recruits the multicomponent 
protein kinase IKK, the IkB kinase, causing IKK complex to phosphorylate IkB, which 
enables the translocation of NFkB to the nucleus, activating NF-kβ (Gewirtz et al., 
2001). Upon NF-κb activation, TNF-α and other pro-inflammatory cytokines are 
produced. This cytokine production in turn activates other inflammatory pathways, such 
as arachidonic acid metabolites,  superoxides, nitric oxide and growth factors (Viscido 
et al., 2005). Other effects of TNF-α include recruitment of neutrophils and monocytes 
via upregulation of adhesion molecules, alteration of cell barrier permeability and 
regulation of apoptosis in target cells through TNF-receptor I binding (Haraoui, 2005). 
 
Numerous reports throughout the literature demonstrate an important role of cytokines 
with anti-inflammatory properties (e.g., IL-10, IL-4 or TGF-β) as negative regulators of 
TNF-α production. For instance, a study by Ebert et al. investigated the release of TNF-
α by resting T cells and monocytes in the presence of antibodies neutralising IL-10, IL-4 
or TGF-β and demonstrated elevated release of TNF-α in such conditions (Ebert, 2005). 
Interestingly, the authors of this study reported that when IL-4 or TGF-β were 
neutralised with appropriate antibodies, elevated levels of IL-10 were produced by 
monocytes, providing an additional protection against the release of exceptionally high 
amounts of TNF-α by these cells. The importance of IL-10 as an endogenous regulator 
of TNF-α is further supported by the findings that, in humans, subjects deficient in 
serum IL-10 levels are more prone to develop chronic inflammatory diseases, e.g. UC 
(MacDonald et al., 2012). 
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In particular, recent work has found that loss-of-function mutations in the genes 
encoding IL-10 and IL-10R are associated with a very early-onset form of IBD that is 
characterized by severe intractable enterocolitis in children (Glocker et al., 2009). 
 
It has been consistently shown that TNF- is increased in the mucosa of IBD patients 
(MacDonald et al., 1990). Increased TNF- expression occurs both in CD and UC, 
however the distribution of producing cells differs: higher levels are seen in deep lamina 
propria of CD than in UC (Breese and MacDonald, 1995). Although many other 
cytokines are involved in the progression of disease, TNF-α represent the central 
cytokine that induces the expression of other important mediators of inflammation 
(Tracey and Cerami, 1993). The strong correlation between increased TNF-α production 
and IBD has been made clear via numerous studies on murine colitis models.  Mice 
over-expressing TNF- (TNFΔARE mice) spontaneously develop an enteritis 
(Kontoyiannis et al., 1999). 
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Figure 1.6: Proposed interaction mechanism of TNFR1 and soluble TNF-. Soluble and 
membrane TNF- activates the classical TNF-α signaling cascade by interacting with TNFRI 
displayed on the surface of immune cells resulting in chemokine and pro-inflammatory cytokine  
expression.  Upon contact with their ligand, TNF receptors form trimers, which causes TRADD 
to recruit TRAF2 and RIP which recruit the IkB kinase, causing the phosphorylation of IKK 
complex enabling the translocation of NFkB to the nucleus, activating NF-kβ. 
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1.5.5 Transmembrane TNF-  and soluble TNF- 
Soluble TNF- is released after the proteolytic cleavage via the metalloproteinase 
ADAM 17 (also known as TACE) between residues  Ala76 and Val 77 (Gearing et al., 
1994). This process is termed ectodomain shedding and represents a critical regulatory 
mechanism, not only for the release of cytokines (e.g. TNF-), but also cytokine 
receptors (e.g. TNFR1 and IL-6R), chemokines (e.g. CXCL16 and CX3CL1), adhesion 
molecules (e.g. L-selectin) and surface proteoglycans. Membrane TNF- is expressed 
on the cell surface of resting natural killer cells as well as of activated T cells and 
macrophages. 
Since membrane TNF-  can function in cell-to-cell contact, it is considered to play a 
critical role in ontogenesis and in local inflammation. Similar to soluble TNF, 
membrane TNF- exists as a homotrimer of uncleaved monomers and binds to both 
subtypes of TNF receptors on target cells, however biological activities are mediated 
mainly through TNFR2 (Grell et al., 1995). By cell death or activation of the target 
cells, expression of membrane TNF- contributes to physiological and pathological 
responses. Cytotoxic activities of membrane TNF has been reported for various tumor 
cells (Horiuchi et al., 2010) and HIV-infected lymphocytes (Lazdins et al., 1997).  The 
importance of  membrane TNF- in inhibition of intracellular pathogens has been also 
reported (Allenbach et al., 2008). In addition, membrane TNF-  has been shown to 
initiate T cell and macrophage migration, granuloma formation and to be effective 
against acute Mycobacterium tuberculosis infection(Saunders et al., 2005). Direct cell-
to-cell contacts through membrane TNF- trigger activation processes in endothelial 
cells, B cells, T cells, monocytes and NK cells (Horiuchi et al., 2010). 
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In contrast to the well characterized functions of membrane TNF- as a ligand, the 
biological functions as a receptor still remain to be clarified. TNF- reverse signaling 
by anti-TNF antibodies has been reported to trigger activation in human T cells and NK 
cells. In addition to its co-stimulatory role and Ca2
+
 signaling inducing capacity in T 
cells (Higuchi et al., 1997), membrane TNF- stimulation can induce the production of 
high amounts of IL-2 and adhesion molecules such as E-selectin (Harashima et al., 
2001). 
Recent clinical and experimental studies have shown that membrane-bound TNF-, 
rather than soluble TNF-, has a major role in driving intestinal inflammation. 
Consistent with this, neutralization of membrane-bound TNF- has been shown to 
induce T cell apoptosis and was effective in suppressing experimental colitis in mice, 
whereas activation of TNFR2 (induced by membrane bound but not soluble TNF) on T 
cells was found to aggravate colitis activity (Perrier et al., 2013). 
Moreover, a recent study has used fluorescently labelled TNF-specific antibodies and in 
vivo imaging to determine the frequency of immune cells that express membrane-bound 
TNF- in the mucosa of patients with Crohn’s disease (Atreya et al., 2014). It was 
found that the presence of high numbers of immune cells expressing membrane-bound 
TNF predicted a positive clinical response to subsequent therapy with TNF specific 
antibodies. Patients in which few immune cells expressed membrane-bound TNF- 
showed little or no response to this type of therapy.  
The first data with ADAM-17 conditional knockout mouse were published in 2007 by 
Blobel et al , who inactivated ADAM-17 in myeloid cells and prevented endotoxin-
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induced lethality of the animals by inhibiting TNF-α shedding and preventing increased 
serum TNF-α (Horiuchi et al., 2007). 
1.5.6 TREM-1 expression by intestinal macrophages in IBD 
Triggering receptor expressed on myeloid cells (TREM)-1 belongs to a family of 
molecules related to natural killer cell-receptors and is expressed on neutrophils,  
mature monocytes and macrophages and has been previously categorized as a mediator 
of acute inflammation (Derive et al., 2010). While circulating serum monocytes express 
TREM-1, most  intestinal macrophages do not express TREM-1 in healthy gut 
(Golovkina et al., 1999). However, intestinal macrophages express TREM-1 at a 
significantly higher level in the inflamed intestinal mucosa of IBD patients (Reinhardt 
et al., 2001). This aberrant TREM-1 expression mediates enhanced secretion of pro-
inflammatory chemokines and cytokines (Schenk et al., 2007). Moreover blocking 
TREM-1 upon induction of experimental colitis attenuates intestinal inflammation. The 
activation of TREM-1 in the presence of TLR2 or TLR4 ligands amplifies the 
production of pro-inflammatory cytokines TNF-α, IL-1β, granulocyte-macrophage 
colony stimulating factor, together with the inhibition of IL-10 release (Bleharski et al., 
2003), thus TREM-1 and TLRs appear to cooperate in producing an inflammatory 
response. The role of TREM-1 as an amplifier of the inflammatory response has been 
confirmed in a mouse model of septic shock in which blocking signaling through 
TREM-1 partially protected animals from death (Gibot et al., 2004). 
 
TREM-1 is one of several TREM and TREM-like molecules, all of which are members 
of the Ig super family (Ig-sf), it contains only a short cytoplasmic tail, and thus signals 
upon association with the promiscuous adaptor molecule DAP12, which possesses two 
immunoreceptor tyrosine-associated activation motifs (ITAMs). Upon ligand binding of 
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TREM-1 the ITAMs of the associated DAP12 become phosphorylated. This allows 
binding of protein tyrosine kinases (such as Syk) via the Src homology 2 (SH2) 
domains. The kinase domain of such tyrosine kinases mediates downstream effects of 
TREM-1 by phosphorylating many proteins. This phosphorylation process may lead to 
Ca
2+
 ion mobilization or activation of extracellular signal-regulated kinases (ERK) 
leading to the transcription of target genes (Colonna and Facchetti, 2003; Wang et al., 
2012). Therefore TREM-1 both directly and indirectly drives a pro-inflammatory 
response by the release of pro-inflammatory cytokines and by increasing the expression 
of receptors of other inflammation pathways. 
The levels of the soluble form of TREM-1 (sTREM-1) correlate with a release of 
cultured human monocytes after stimulation with LPS. sTREM-1 was also detectable in 
the serum of endotoxemic mice as early as 1 h after LPS challenge. This is consistent 
with the role of TREM-1 in the very early phases of the innate immune response to 
infection (Brandl et al., 2007; Putsep et al., 2000). The mechanism by which sTREM-1 
is released is not clearly elucidated but seems to be related to an increased transcription 
of the TREM-1 gene. Nevertheless, although incubation with a protease inhibitor 
cocktail does not alter the sTREM-1 release, cleavage of the surface TREM-1 from the 
membrane cannot be totally excluded. Interestingly, stimulation of human monocytes 
with such proinflammatory cytokines as TNF-, IL-1β and IFN-γ induced very small 
sTREM-1 release unless LPS is  added as a co-stimulus (Bleharski et al., 2003). 
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1.6 Aims of the PhD project: 
 
1. To set up a robust and reliable method for the isolation of intestinal 
macrophages from healthy and inflamed gut resection specimens. 
 
2. To perform a detailed phenotypic characterisation of intestinal lamina propria 
macrophages in comparison to circulating monocytes in control subjects and IBD 
patients. 
 
3. To identify markers able to distinguish the populations of resident and recruited, 
resting and activated macrophages in healthy control and in IBD mucosa. 
 
4. To study the production of TNF- by intestinal macrophages in control subjects 
and IBD patients. 
 
5. To study the behaviour of intestinal macrophages compared to circulating 
monocytes with regards to their key functions such as cytokine release. 
 
6. To perform a gene expression array of intestinal macrophages in healthy control 
subjects and IBD patients. 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
CHAPTER 2 
Materials and methods 
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2.1 Patients and tissues  
Colonic biopsies or surgical specimens were taken from macroscopically and 
microscopically inflamed or uninflamed mucosa of patients affected by CD and UC. 
Diagnosis of CD and UC was ascertained according to the usual clinical criteria, and the 
site and extent of the disease were confirmed by endoscopy and histology. In CD 
patients, disease activity was assessed by Crohn’s Disease Activity Index (Best et al., 
1976). Patients with scores below 150 were classified as being in remission, whereas 
those with scores over 450 had severe disease (Best et al., 1976). In UC patients, disease 
activity was assessed according to the Clinical Activity Index of Rachmilewitz 
(Rachmilewitz, 1989). Clinical remission was defined as a score below 4. Surgical 
specimens were also taken from uninflamed areas of strictured and non-strictured ileum 
of patients with fibrostenosing CD. Moreover, mucosal samples were collected 
perendoscopically from the ileum or the colon of subjects who had functional diarrhoea 
at the end of their diagnostic work-up. Intestinal samples were also collected from 
macroscopically and microscopically unaffected ileal or colonic areas of patients 
undergoing intestinal resection for colon cancer. Some samples were used to isolate 
lamina propria mononuclear cells (LPMCs), others for organ culture experiments, and 
others were snap frozen in liquid nitrogen and stored at -70°C for subsequent analyses. 
 
2.2 Buffers, media and solutions 
Buffers and stock solutions were prepared according to standard procedures using water 
(H2O) or phosphate buffered solution (PBS). Ready-to-use Roswell Park Memorial 
Institute-1640 medium (RPMI-1640) was bought from Invitrogen. Antibiotics (Aldrich, 
Poole, UK) were prepared as stock solutions, filter-sterilized (0.2 μm) and added to 
media. 
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2.3 Ex vivo organ culture 
Perendoscopic mucosal biopsies from inflamed or uninflamed areas of CD and UC 
patients were placed (one biopsy per well) in 24-well plates (VWR International, 
Lutterworth, UK) in 300 µl serum-free HL-1 medium (Cambrex BioScience, 
Wokingham, UK) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin, 
and cultured at 37°C, 5% CO2 in order to evaluate spontaneous pro-inflammatory 
cytokine production. After 24h ex vivo culture, supernatants of mucosal biopsies were 
collected and stored at -70°C until cytokines production was quantified using DuoSet 
Enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Abingdon, UK). 
 
2.4 Measurement of cytokine production by ELISA 
Ninety-six-well microplates (VWR International) were coated with anti-IL-6 (360 
µg/mL; R&D Systems), anti-IL-8 (720 µg/mL; R&D Systems) anti-IL-24 (360; µg/mL 
R&D Systems) anti-TNF- (480 µg/mL; R&D Systems) IL-1 (480 µg/mL; R&D 
Systems) and sIL-6R (360 µg/mL; R&D Systems) overnight at room temperature. The 
plates were washed 3 times with PBS 0.05% Tween (Sigma-Aldrich, Poole, UK) before 
being blocked with PBS 0.1% bovine serum albumin (BSA) (IL-6, IL-24, TNF-, IL-1 
and sIL-6R) or 0.01% BSA (IL-8) for 1h at 37°C. The plates were then washed and 
incubated with detection antibodies for 2 h and washed again, incubated with serially 
diluted recombinant cytokine standards and diluted samples (1:10 for IL-6, 1:50 for IL-
8, undiluited for IL-24, 1:2 for TNF- 1:5 for IL-1 and 1:5 for sIL-6R) for 2h at 37°C, 
before being washed again and incubated with biotinylated anti-IL-6 (9µg/ml), anti-IL-8 
(3.6 µg/ml), anti-IL-24 (72 µg/ml) anti-TNF- (4 µg/ml), anti- IL-1 (4 µg/ml ) and 
anti- sIL-6R (2 µg/ml). 
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Plates were then washed and incubated with Streptavidin-HRP (1:200) for 20 min. After 
washing, substrate solution was added for 20 minutes at room temperature and finally, 
without washing 50 µl of stop solution was added to each well. The optical density of 
each well was determined immediately after using a microplate reader at 450 nm. 
 
2.5 LPMCs isolation and culture 
LPMCs were isolated as previously described (Di Sabatino et al., 2007). Briefly, in 
order to remove both epithelial cells and intraepithelial lymphocytes, the mucosa was 
incubated for 10 min at 37°C in calcium-and magnesium-free Hanks’s balanced salt 
solution (HBSS) (Life Life Technologies, Paisley, Scotland) with 1 mM EDTA (Sigma-
Aldrich, Poole, UK) for three times. After stirring for 1h at 37°C, the supernatant was 
removed and the remaining tissue was disrupted mechanically into smaller pieces of 
approximately 3-4 mm and incubated, for1 h, with continuous agitation at 37 °C in 
RPMI medium (Sigma-Aldrich, Poole, UK) supplemented with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, Poole, UK), 100 U/ml penicillin and 100 µg/ml streptomycin, 
and treated with 1A collagenase (1 mg/ml; Sigma-Aldrich, Poole, UK) and DNase I (10 
U/ml; Roche, Mannheim, Germany). After washing, LPMCs were isolated with Ficoll 
density centrifugation using a Ficoll-Paque Plus gradient (Amersham Pharmacia 
Biotech, Uppsala, Sweden) following the manufacturer’s protocol, and kept on ice until 
used. 
Freshly isolated LPMCs were cultured (1 × 106 cells/well) in complete medium, at 
37◦C, 5% CO2 for 4 h in 24-well plates (VWR International) with medium alone or 
with Lipopolysaccharide (LPS) (100 ng/m; Sigma-Aldrich, Poole, UK) or with 
GW280264X (10µM/ml) or dimethyl sulfoxide (DMSO) (1µg/ml; SignaAlrich, 
Pool,UK) or phorbol 12-myristate 13-acetate (PMA) (50 ng/ml; Sigma-Aldrich, Poole, 
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UK) + Ionomycin. After culture, LPMCs supernatants were collected and stored at 
−70◦C. 
 
2.6 PMA + ionomycin stimulation  
Two million cells from normal colon were incubated with and without PMA and 
ionomycin for 4 h. After 2h, 2μm of monensin (BioLegend, Cambridge, England) were 
added in order to prevent cytokine secretion. Cells were washed in PBS and then 
incubated with live/dead
® 
fixable blue dead cell stain kits (Molecular Probes; Life 
Technologies, Paisley, Scotland) as per the manufacturer's guidelines. From this point 
supernatant was collected and stored at -80°C and cells were stained. 
 
2.7 Isolation of PBMCs and cell culture 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers, 
CD and UC patients after informed consent was obtained. Briefly, the blood was diluted 
1:1 in PBS (without Ca
2+
, Mg
2+
) and 25 ml loaded on Ficoll in 1:1 ration. After 
centrifugation at 21°C for 20 minutes at 1500 rpm the buffy coat was collected into a 50 
ml tube and washed twice in PBS (without Ca
2+
, Mg
2+
). Finally, the pellet was 
resuspended in 1 ml PBS (without Ca
2+
, Mg
2+
) and cells were counted using 
haemocytometer. Cells were then cultured in RPMI 10% human 
serum/penicillin/streptomycin/L-glutamine. 
CD14
+ 
human monocytes were purified from PBMCs by positive selection using anti-
CD14
 
magnetic beads following manufacture instruction (Miltenyi Biotec Bergisch 
Gladbach, Germany).  
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2.8 Flow cytometry and antibodies 
2.8.1 Surface staining 
After isolation of LMPCs, 1x10
6
 cells were washed in 1 ml of FACS buffer, 
resuspended in 100 µl of FACS buffer (PBS + 2mM EDTA + 2% BSA), and then 
incubated at 4 °C with 20 µl of Human Fc Receptor Binding Inhibitor (eBioscience; 
Hatfield, England) to reduce non-specific binding via Fc receptors, then incubated with 
the relevant primary antibodies (as detailed in Table 2.1) for 20-30 minutes at 37°C 
protected from the light. Cells were then washed three times in ice cold FACS buffer 
and analysed using LSRII flow cytometry (BD Bioscience Oxford, England). Dead cells 
were excluded from analysis by adding 0.25 µg/test of 7-aminoactinomycin D (7-AAD; 
BD Biosciences, Oxford, England) to each sample immediately before analysis. 
Appropriate isotype controls were included in all experiments. As detailed in Table 2.1, 
isotype controls were purchased from the manufacturer of the antibodies. All data 
generated were analysed using FlowJo software (Tree Star Inc, OR, USA). 
 
 
 
 
 
 
 
 
 
 
 
69 
 
ANTIBODY Clone  Isotype  Company Format 
CD3 
CD3 
HIT3a 
WM53 
Mouse IgG2a, 
κ 
Mouse IgG1, κ 
Biolegend 
Biolegend 
PE 
APC 
CD45 
CD45 
HI30 
HI30 
Mouse IgG1, κ 
Mouse IgG1, κ 
BD Biosciences 
Biolegend 
APC 
Pacific 
Blue™ 
HLA-DR 
HLA-DR 
HLA-DR 
TU36   
G46-6 (RUO) 
L243 
Mouse IgG2b, 
κ 
Mouse IgG2a, 
κ 
Mouse IgG2a, 
κ 
BD Biosciences 
BD Biosciences 
Biolegend 
PE 
PE-Cy5 
PerCP-Cy5.5 
CD33 
CD33 
WM53 
WM53 
Mouse IgG1, κ 
Mouse IgG1, κ 
Biolegend 
Biolegend 
APC 
PE 
CD68 
CD68 
Y1/82A 
Y1/82A 
Mouse IgG2b, 
κ 
Mouse IgG2b, 
κ 
Biolegend 
Biolegend 
FITC 
PerCP-Cy5.5 
CD14 
CD14 
CD14 
CD14 
HCD14 
HCD14 
M5E2 
M5E2 (RUO) 
Mouse IgG1, κ 
Mouse IgG1, κ 
Mouse IgG2a, 
κ 
Mouse IgG2a, 
κ 
Biolegend 
Biolegend 
Biolegend 
BD Biosciences 
FITC 
PerCP-Cy5.5 
Pacific 
Blue™ 
BV650 
CD206 15-2 Mouse IgG1, κ Biolegend APC-Cy7 
CD64 10.1 Mouse IgG1, κ Biolegend PE 
TNF- MAb11 Mouse IgG1, κ Biolegend PE-Cy7 
Membrane 
TNF- 
Cl 6401 Mouse IgG1 R&D Fluorescein 
Lineage cocktail UCHT1, 
HCD14, 3G8, 
HIB19, 2H7, 
HCD56 
Mouse IgG1, κ; 
Mouse IgG2b,κ 
Biolegend Lineage 
cocktail 
 
Table 2.1: List of Monoclonal Antibodies for Flow Cytometry: Primary antibodies were 
conjugated to either APC, FITC, PE, PerCP-Cy5.5, PE-Cy5,  PE-Cy7, APC, APC-Cy7, Alexa 
fluor 488, BD Horizon V650, PE-Cy5, Pacific blue, Fluorescein. 
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2.8.2 Intracellular cytokine staining
 
  
 One million 
 
LPMCs were washed with 3 times  with FACS buffer and incubated (with 
or without extracellular markers) for 30 min with 1 μl of Fixable Blue Dead Cell stain 
kit (for UV excitation, Molecular Probes; Life Technologies Paisley, Scotland) as the 
manufacturer's guidelines, for 20-30 minutes protected from light. 
After 20 min the cells were washed and fixed with 100 µl of Fixation Buffer, 
(containing 4% formaldehyde from the Intracellular Fixation & Permeabilization Buffer 
Set, eBioscience; Hatfield, England) in the dark for 15 minutes in ice.  Without 
washing, 1 ml of 1X Permeabilization Buffer (containing 0.1% saponin and 0.09% 
sodium azide) (Intracellular Fixation & Permeabilization Buffer Set, e Bioscience; 
Hatfield, England), was added to each tube. Prior to a further incubation with Human Fc 
Receptor Binding Inhibitor, cells were then resuspended in Permeabilization buffer 1X 
together with the appropriate fluorochrome-conjugated cytokine-specific antibodies for 
20 minutes protected from light. Cells were then washed with 1X Permeabilization 
Buffer, resuspended in FACS buffer and analysed by flow cytometry. 
Data from about 250,000 cells was collected, FSC and SSC were analysed on linear 
scales. All data generated were analysed using FlowJo software (Tree Star Inc, OR, 
USA).  
 
2.8.3 Flow cytometry gating strategy  
Events were gated to eliminate artefacts caused by poor flow and 7-aminoactinomycin 
D (7-AAD; BD Pharmingen) was used to exclude dead cells or LIVE/DEAD Fixable 
Blue Dead Cell (depending on whether the analysis was for extracellular or intracellular 
staining).  
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Seven-AAD is a membrane impermeant dye, generally excluded from viable cells 
which bind to double stranded DNA by intercalating between base pairs in G-C-rich 
regions. The LIVE/DEAD® Fixable Blue Stain is an amine reactive dye that binds 
covalently to intracellular and extracellular amines, preserving the staining pattern 
following formaldehyde fixation.  
The doublets corresponding to cell aggregates were also excluded by the FSC-A/FSC-H 
and SSC-A/SSC-H profile and single cells were further analysed.  
 
 2.9 RNA extraction 
RNA was extracted using trizol-chloroform isolation method. The cells were lysed by 
adding 200 µl of trizol per 10
6 
cells after removal of culture media. If tissue material 
was used for RNA extraction, 400 µl of trizol was used per biopsy size tissue material. 
The lysates were stored at -70°C for subsequent RNA extraction or used immediately 
The RNA extraction was performed using the Qiagen RNeasy kit (Qiagen, Manchester 
UK). First, the trizol lysates were mixed with 1/5
th
 volume of chloroform and incubated 
for 5 minutes on a shaker (650 rpm) at room temperature and centrifuges at 16,000xg 
for 3 minutes. The clear aqueous phase was transferred to a clean eppendorf and an 
equal volume of 70% ethanol was added to each sample at the time. The samples were 
applied to a Qiagen RNeasy mini-column and centrifuged for 30 seconds at 9,000xg and 
washed two times with RW1 buffer (provided in the kit). Additionally, DNase digestion 
was included for more complete DNA removal using Qiagen RNase-free DNase Set. 
The DNase-1 stock was initially prepared following the manufacturer’s instruction and 
10 µl of DNase-1 stock solution was dissolved in 70 µl of RDD buffer (provided in the 
kit) and 80 µl of final volume was applied onto each column and incubated for 
maximum 15 minutes at room temperature. Next, the columns were washed twice with 
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RPE buffer (provided in the kit) and eventually columns were transferred to fresh 
eppendorfs and RNA was eluted using RNase-free water, also provided in the kit. RNA 
was quantified using a Nanodrop spectrophotometer (Thermo Scientific) according to 
the manufacturer’s instruction. Samples were stored at -70°C. 
 
2.10 Reverse Transcription and RT2 Profiler Array PCR 
Prior to  RT
2 
Profiler Array PCR, reverse transcription was performed with the RT2 
First Strand Kit (Qiagen, Manchester Limited, UK) with 340 ng of RNA per sample 
accordingly to manufacturer’s instructions in a maximum volume of 8 µl. A preliminary 
genomic elimination step was performed by adding 2 l of GE buffer/sample (included 
in the kit). Samples were incubated at 42°C for 5 minutes. Next, to set up the reverse 
transcription 4 l of 5XBC3 buffer, 1 l of P2 buffer, 2 l RE3 buffer and 3 l of 
RNase-free water were added to each RNA sample (all buffers were included in a kit). 
Prepared samples were incubated at 42°C for 15 minutes and then 95°C for 5 minutes 
on the thermal cycle. After incubation, samples were cooled on ice for 1 minute and 91 
l of RNase-free water was added to each sample and all was mixed very gently. Next, 
102 l of cDNA material was added to PCR premix (448 l of RNase-free water mixed 
with 550 l of RT2 Syber Green ROX qPCR Mastermix (Qiagen, cat no: 330401). 
Finally, the master mix (10 l/well) was loaded onto Human Common Cytokine RT2 
Profiler PCR Array plate (Qiagen PAHS-021E-4). The plate was centrifuged for 5 
minutes at 524xg and run on ABI7900HT (Applied Biosystems) with cycling 
conditions: 1 hot start cycle at 95°C for 10 minutes; 40 PCR cycles of 95°C for 15 
seconds, and 60°C for 1 minute, then thermal denaturation cycle of 95°C for 15 seconds 
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(ramp rate 100%), 60°C for 15 minutes (ramp rate 100%), and 95°C for 15 seconds 
(ramp rate 2%). 
The raw Ct values were normalized to GAPDH and converted to copy numbers. 
Undetected genes were eliminated from further analysis. Fold changes and P-values 
were obtained by fitting a linear model to the normalized copy number for each gene. 
Table 2.2 represent the set of all 84 genes included in RT-PCR Assay. 
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BMP1 BMP2 BMP3 BMP4 BMP5 BMP6 BMP7 BMP8B CSF1 CSF2 FAM3
B 
FASLG 
FIGF GDF1
0 
GDF11 GDF2 GDF3 GDF5 MSTN GDF9 IFNA1 IFNA2 IFNA4 IFNA5 
IFNA8 IFNB1 IFNG IFNK IL10 IL11 IL12A IL12B IL13 TXLNA IL15 IL16 
IL17A IL17B IL17C IL25 IL18 IL19 IL1A IL1B IL1F10 IL1F5 IL1F6 IL1F7 
IL1F8 IL1F9 IL2 IL20 IL21 IL22 IL24 IL3 IL4 IL5 IL6 IL7 
IL8 IL9 INHA INHBA LEFTY2 LTA LTB NODAL PDGFA TGFA TGFB1 TGFB2 
TGFB
3 
TNF TNFRSF11
B 
TNFSF1
0 
TNFSF1
1 
TNFSF1
2 
TNFSF1
3 
TNFSF13
B 
TNFSF1
4 
TNFSF
4 
CD70 TNFSF
8 
B2M HPRT
1 
RPL13A GAPDH ACTB HGDC RTC RTC RTC PPC PPC PPC 
 
Table 2.2: List of 84 genes panel for RT-PCR Array   Fields in gray and green represent 
housekeepers and controls, respectively. The reaction was set for 340 ng per sample/genes 
panel.  
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2.11 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 4 (GraphPad 
Software, San Diego, CA) using the unpaired t test, some samples were also analysed 
using paired T-test when appropriate. Statistical analyses was assumed if the p value 
was <0.05. 
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CHAPTER 3 
Results: Phenotypic characterization of intestinal macrophages in the 
inflamed and normal colon 
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3.1 Introduction 
It is known that inflammatory macrophages are recruited to the intestine in CD  and UC 
(Heinsbroek and Gordon, 2009). A variety of different receptors play a role in 
generating and facilitating inflammatory macrophages in pathogenesis of IBD. 
However, the roles of macrophages and their receptors in IBD are still poorly 
understood (Mowat and Bain, 2011).  
This chapter describes the strategies I developed to isolate different populations of 
macrophages from the gut of IBD patients and those with colon cancer. 
 
3.2 Gating strategy 
Phenotypic analysis of intestinal macrophages was conducted in order to have a more 
detailed characterization of these populations. Macrophages were isolated from LPMCs 
prepared from resected bowel of patients with CD, UC or colon cancer by collagenase 
digestion and enrichment using density gradient centrifugation. Cells were then 
analysed by flow cytometry in order to determine their surface antigen, intracellular 
antigen and cytokine expression.  
Using this procedure, a heterogeneous population of cells was identified by adjustment 
of FSC and SSC properties (Figure 3.1, G5). These two parameters highlighted the 
difference in size and granularity allowing the exclusion of lymphocytes from the rest of 
the cells. The same gating procedures were applied on control, CD and UC samples. 
Approximately more than 50% of the live-gated cells expressed CD45, indicating they 
were populations of haematopoietic origin (Figure 3.2). The other cells were probably 
fibroblasts and a few contaminating enterocytes. A control isotype matched antibody 
labelled with the same fluorochrome as the specific anti-CD45 mAb was used to 
identify CD45
+
 population within the LPMCs. 
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3.3 CD33 expression by control and IBD LPMCs 
To increase the understanding into the phenotypic heterogeneity of the different 
macrophage populations, the expression of various myeloid cell markers was assessed.  
The marker CD33 was used to identify the entire myeloid compartment of CD45
+
 7-
ADD
-
 cells in the LPMCs of control, CD and UC patients. 
CD33 is a 67 kDa glycoprotein member of the Ig superfamily, expressed in early 
myeloid progenitors. It is a member of the sialoadhesin family of sialic acid-dependent 
cell adhesion molecules  (Munday et al., 1999) but the function and binding properties 
of CD33 are still unknown. 
As shown in Figure 3.3 there is no significant difference in the percentages of CD33
+
 
cells between the control, CD and UC groups. Seventeen ± 2.4% of LPMCs in normal 
colon expressed CD33, and in the LPMCs of CD and UC patients, 15.6 ± 2.7% and 17.4 
± 2.5% were respectively CD33
+
.
 
To exclude lymphocytes which may be CD33
+
 a gating strategy was adopted in the 
initial experiments for CD3 and CD33 expression. Using LPMCs from normal colon, 
total myeloid cells were identified amongst live leukocytes (CD45
+
 live/dead
-
) as 
CD33
+   
and CD3
+
 lymphocytes within the same gated cells (CD45
+
 Live dead
-
) (Figure 
3.4). The absence of double-positive expression on LPMCs shows that the majority of 
CD33 myeloid cells are CD3
-
. Moreover a much smaller population (Figure 3.4 B) of 
CD3
+
 cells are CD33
+
 which can be clearly distinguished from the larger myeloid 
CD33
+
 cells (Figure 3.4 C). 
 
3.4 CD68 and CD33 expression by control and IBD LPMCs 
The intracellular marker CD68 (the human homologue of mouse macrosialian) is the 
gold standard macrophage marker in man, CD68 is a heavily glycosylated protein 
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localised in the lysosomal membranes of macrophages (Smythies et al., 2005). 
Although the biologic functions of CD68 have not been fully defined, it is known that 
CD68 serves as a scavenger receptor for oxidized low density lipoproteins and may also 
be involved in cell-cell interactions (Ramprasad et al., 1996). Consistent with previous 
findings, some cells in live
+ 
gated
 
LPMCs (Figure 3.5 A) express intracellular CD68, in 
contrast to the CD3
+
 population, which is negative for CD68.  
To determine whether CD68-expressing macrophages were increased in UC and CD, 
LPMCs from 13 patients with CD, 10 patients with UC and 10 control patients were 
analysed. Control LPMCs expressed a markedly lower percentage of CD68
+
 cells than 
the LPMCs from IBD patients (Figure 3.5 C).   
The next studies were therefore to determine in more detail other markers on CD45, 
CD33 and CD68 cells. Double-staining for intracellular CD68 and CD33 was 
performed in LPMCs from IBD patients and controls (Figure 3.6). The percentage of 
double positive CD68
+
CD33
+ 
macrophages in control LPMC  was significantly lower 
(5.7 ± 0.9%) than in the CD LPMCs (11.4 ± 2.1%). Moreover the frequency of 
CD33
+
CD68
+
 LPMCs in UC (11.77% ± 2.2%) was significantly higher than normal 
mucosa. 
 
3.5 Identifying dendritic cells in the gut 
One of the main difficulties in achieving a better understanding of intestinal 
macrophages during steady state and inflammatory conditions is discriminating them 
from dendritic cells which also express CD33. 
To do this, were first identified macrophages as lineage
+
 HLA-DR
+
 and dendritic cells 
as lineage
- 
HLA-DR
+ 
cells. Dendritic cells and macrophages show two distinct 
populations with differential expression of CD33 (Figure 3.7). While 78.2 ± 5.5% of 
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cells in the lineage
+
 HLA-DR
+ 
population expressed CD33, the percent of dendritic cells 
expressing CD33 was 36.0 ± 4.3%. 
 
3.6 CD33 as an alternative to CD68 for functional application 
Functional studies need the development of relatively rapid isolation of pure 
populations of cells. Therefore the next experiments were designed to compare MACS 
as opposed to FACS methodology.  
CD33 and CD68 were used to stain LPMCs and the cells were sorted by FACS Aria.  It 
took 3-4 hours to run all the cells and ended up isolating an average of 15% of 
CD33
+
CD68
+
 cells, with a purity of 85 ±0.8%.  Thus, FACS provided a relatively high 
purity of CD33
+
 CD68
+
 cells but the sort time was too long and expensive. A major 
issue however is also that CD68 is an intracellular marker and so cells have to be 
permeabilised, which renders them unusable for functional studies. 
Also, since this project is part of a more extensive study conducted with fellow PhD 
student Aneta Kucik, who performs Chromatin Immunoprecipitation (ChIP) on isolated 
intestinal macrophages, cell isolation techniques were optimised in order to obtain a 
higher cell yield. 
MACS technology was tested next, using CD33 as a marker for macrophages. For 
intestinal macrophages MACS separation overall was better than  FACS, although it  
reached only 5.6% ± 0.5 of the LPMCs,  but a  greater  degree of purity was achieved as 
compared to sorting (close to 98±0.6%) after ~ 1.5 h (Figure 3.8).  
 Hence, MACS sorting achieves the highest purity of cells in a shorter time but has 
poorer yields. For the purpose of functional studies it was also important for us to 
determine the cell yields from control, CD and UC tissues by MACS sorting.  Table 3.1 
shows the number of cells obtained after isolation of LPMCs using CD33
+
 magnetic 
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beads. It was possible to obtain an average of 5.4 (±1) x10
6
 CD33
+ 
cells, starting from 
100(±17) x10
6
 LPMCs cells in control tissues, 4.5(±0.4) x10
6
 CD33
+
 cells from 67.8 
(±11) x10
6
 LPMCs in CD, and 6.8 (±2.2) x10
6
 CD33
+
 cells starting from 114.1(±28.4) 
x10
6
 LPMCs) in UC.  
 
3.7 CD14 and CD33 expression by control and IBD LPMCs 
CD14 is the classical surface marker used to identify macrophages and it was therefore 
of interest to determine if the LPS unresponsive macrophages in normal LPMC express 
CD14 in control tissues and in IBD tissues (Figure 3.9). 
In normal LPMC, CD33
+
 cells were mostly CD14
-
. However in inflamed and 
uninflamed IBD tissues there was a large increase in CD14
+
 CD33
+ 
cells.  
As shown in the figure 3.9 B there was a significant increase of CD33
+
CD14
+
 LPMCs 
in the inflamed (9.9% ± 2.7, p=0.01) colon of UC patient compared to controls.  Also, 
the mean percentage of CD33
+
CD14
+
 LPMCs in the inflamed colon of CD patients 
(5.2% ± 0.9) was significantly (p= 0.04) higher compared to controls. 
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3.8 Discussion 
The results presented in the first results chapter describe the approach of distinguish 
intestinal macrophages by studying the best gating strategy in order to exclude most of 
the cells of the lamina propria which were not macrophages. In more detail it was 
showed that the CD33 myeloid marker is expressed both in control  and IBD tissues, 
that high upregulation of CD68
+
 LPMCs is seen in the LPMCs of IBD patients, and that 
the frequency of CD33
+
CD14
+
 LPMCs  was greater in  the inflammatory intestine of 
active CD and UC patients relative to non-IBD control patients. Of interest the 
proportion of CD33
+
CD14
+
 LPMCs was higher in UC patients.  
Previous studies have described the significantly increase of inflammatory macrophages 
in the patients with IBD (Kamada et al., 2008). It was also shown that CD14
+
 and TLR
+
 
myeloid cells are  increased in the lamina propria of patients with IBD (Rogler et al., 
1998) (Smythies et al., 2005) and that proinflammatory macrophages, such as TREM-1
+
 
macrophages, are increased in intestinal mucosa and contributed to the intestinal 
inflammation (Schenk et al., 2007). 
The characterization of intestinal macrophages has been extremely hard for many 
reasons. In this chapter I set out to optimise a protocol for the purification and 
characterisation of myeloid cells in the human colon using multi-parameter flow 
cytometry.   
At the beginning of the project I was specifically interested in testing CD33 as a marker,  
based on previous findings by Kamada and colleagues (Kamada et al., 2008). By using 
anti-CD33 I was able to define heterogeneous myeloid subsets in control and 
inflammatory conditions. Hence myeloid cells from LPMCs of control, CD and UC 
patients, inflamed or non-inflamed, were identified amongst live leukocytes 
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(CD45
+
Live
+
) as CD33
+
 and were seen in LPMCs from control, CD and UC tissues 
(Figure 3.3). In contrast to CD33, CD68 expression by LPMCs was higher in inflamed 
IBD, especially in CD (Figure 3.5) compared to normal mucosa. This is consistent with 
CD showing a more mononuclear cell infiltrate. Moreover neither CD33
+
 nor CD68
+
 
populations expressed CD3, ensuring that the population of myeloid cells were likely to 
represent just myeloid cells with no lymphocyte contamination (Figure 3.3 and 3.5). 
The presence of CD68
+
 cells in control mucosa has been recognised for many years. In 
the colon, these cells reside just below the epithelium, optimally sited to phagocytose 
invading pathogens and commensals that leak through the barrier. Of special interest 
was the number of macrophages which significantly increase in IBD. The increased 
numbers of CD68
+
 cells in inflamed mucosa was shown by immunofluorescence  many  
years ago and their co-expression of CD14  suggests recruitment of new 
monocytes/macrophages from peripheral blood (Rugtveit et al., 1994). 
CD33 is not a specific marker for macrophages but it is also expressed on granulocytes 
and dendritic cells (Lock et al., 2004). However the methodology used to process 
immune cells from lamina propria require the step of using a density gradient 
centrifugation which prevents the inclusion of the granulocyte compartment. Hence the 
only major adversity in using CD33 as unique marker for macrophages is that dendritic 
cells, express CD33. However our results using lineage markers and HLA-DR showed 
that most of the CD33+ cells were macrophages. 
It has been reported that human intestinal macrophages do not express typical 
macrophage innate-immune receptors, such as CD14 or TLRs, and that they exhibit 
anti-inflammatory anergic phenotypes (Smith et al., 2001). Consistent with the anergic 
nature of intestinal macrophages, my data showed that some CD33
+
 macrophages in 
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control mucosa express CD14 but the proportion of cells expressing CD14 is lower in 
comparison to cells from IBD patients (Figure 3.9). The number of CD33
+
CD14
+
 
LPMCs subsets was increased not only in inflamed mucosa but also in uninflamed 
mucosa of CD and UC.  The significant accumulation of CD14
+
 LPMCs that expands 
preferentially in IBD inflamed tissue may suggest two possibilities; the first is that these 
two different intestinal subsets are derived from different subsets of monocyte, such as 
inflammatory or resident monocytes as previously reported (Geissmann et al., 2003; 
Gordon and Taylor, 2005). The second suggests that monocytes enter the colonic 
mucosa and differentiate in macrophages in situ with acquisition of certain markers and 
loss of others such as the typical macrophage innate-immune receptors, such as CD14 
or TLRs (Smythies et al., 2005).  
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Table 3.1: Numbers and percentage of CD33
+ 
LPMCs obtained after MACS sorting. 
 
 
 
 
 
 
 
 
 Number of 
Cells before 
Sorting ±SD 
(*106) 
Number of 
Cells after  
Sorting(*10
6
) 
% of Cells 
Yields after 
Sorting 
Control 100 ±17.0 5.4 (±1.0) 6.0 (±0.8) 
CD 67.8 ±11.0 4.5 ( ±0.4) 6.1 (±0.7) 
UC 114.1(±28.3) 6.8 (±2.2) 4.8 (±0.9) 
86 
 
 
 
Figure 3.1: Gating strategy.  LPMCs were isolated from control, Crohn’s disease (CD) and 
ulcerative colitis (UC) tissues. Dead cells were excluded using 7-aminoactinomycin (7-AAD) or 
LIVE/DEAD Fixable Blue Dead Cell (G2).  FSCA/FSC-H and SSC-A/SSC-H were used to 
discriminate doublets (G3-G4). Representative dot plots showing the identification of single 
cells based on SSC-A vs FSC-A was used to discriminate lymphocytes from the rest of the cells 
(G5). 
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Figure 3.2: Refined gating strategy for analysis of LPMCs. Representative dot plot showing 
the expression of CD45 by FSC
+
SSC
+
 live LPMCs  from control , CD and UC tissues . Gating 
strategy employed to define CD45
+ 
cells by comparing specific anti mAb staining with a 
matched fluorochrome conjugated isotype. 
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Figure 3.3: Myeloid cell populations defined by CD33 expression. A.  Representative dot 
plots of CD33 staining on  CD45
+
  live LPMCs cells.  B.  The mean proportion of CD33
+
 cells 
within each population. The percentage of CD33
+ 
cells shows no significative difference 
between control, CD and UC tissues.  Results are representative of three individual experiments 
with N=27 for control experiment, N=15 for CD and N=20 for UC. 
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Figure 3.4: FSC/SSC properties of LPMCs. LPMCs pooled from 3 control  patients were 
analysed for the expression of CD33 and CD3 by flow cytometry. A.  Representative dot plot of 
CD33 and CD3 expression by live-gated CD45
+ 
cells and FSC and SSC properties of the 
individual subsets are shown.  B.  Results are representative of at least three experiments. 
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Figure 3.5: CD68
+
 cells in normal and IBD mucosa. Live-gated LPMCs A. from control 
patients were assessed for the expression of surface CD3 and cytoplasmic CD68 expression.  B. 
Representative plots showing CD68 expression by control, CD and UC tissues.  C. The data 
shown are representative of n=14 control subjects, n=14 inflamed mucosa of CD and n=10 
inflamed mucosa of UC patients.*p (CD versus Control) = 0.0143; *p (UC versus Control) 
=0.0203. 
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Figure 3.6: Percentage of CD33
+
CD68
+
 LPMCs in control and IBD mucosa. LPMCs from 
control subjects and from patients with active IBD were analysed by FACS for CD68 and CD33 
expression. A. Representative dot plots showing CD68 and CD33 expression by live-gated 
(CD45
+
) LPMCs obtained from control, CD and UC tissues. B. CD33
+
CD68
+
 expression in 
controls (n=9) was lower than in in IBD samples CD (n=10) and UC (n=12) (p<0.05).  
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Figure 3.7: DCs and macrophages in LPMCs: LPMCs from control samples were analysed 
by FACS for Lineage markers, HLA-DR, CD33 and CD45. A. Representative lineage cocktail 
and HLA-DR expression by LPMCs. B. Representative CD45 and CD33 expression by DC and 
macrophages. C. Percentage of Lin
+ 
HLA-DR
+
 and Lin 
-
HLA-DR
+
cells expressing CD33. Data 
are representative of n=6 independent experiments. Bars represent mean percentage of 
expression and error bars denote SEM. 
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Figure 3.8: FACS sorting of overall LPMCs compared to MACS sorting. Following 
isolation of  LPMCs from control , CD and UC mucosa,  CD33
+
 cells  were positively selected 
by MACS sorting or CD33
+
CD68
+
 by FACS-based purification. The percentage showed for 
each method is the result of control, CD and UC pooled together (n=5). 
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Figure 3.9: CD33
+
CD14
+
 cells and CD33
+
CD14
-
  cells analysed for expression of CD45
+
. 
LPMCs were analysed by FACS for CD14 and CD33 cell-surface expression; two subsets were 
identified, CD33
+
CD14
+
 and CD33
+
CD14
-
. A. The plots are representative data of the average 
values for each experimental group. B. Percentage of CD14+ intestinal macrophages among 
CD33
+
 cells from control tissues, uninflamed tissue from   UC patients, inflamed tissue from 
patients with UC, uninflamed mucosa from CD tissues, and inflamed tissue from patients with 
CD. *P < 0.05, **P < 0.01. CD14-expressing CD33 LPMCs were increased in the inflamed 
intestinal mucosa of patients with IBD. Recruited CD33
+
CD14
+
 LPMCs show a significative 
increase in inflamed IBD (C) The percentage of CD33
+
CD14
-
 show no significative difference 
between control , CD and UC. 
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CHAPTER 4 
Results: Phenotypic characterization of resident and recruited 
intestinal macrophages in the inflamed and normal colon 
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4.1 Introduction 
In the previous chapter, it was shown the CD33 cells in the gut comprise two main 
populations that differ in the expression of CD14. Those with low levels of CD14 
dominated the normal mucosa, whereas CD14
+ 
cells were expanded in the tissues in 
IBD. 
In vitro, macrophages can be categorized into two subgroups namely M1 pro-
inflammatory macrophages and alternatively activated M2 macrophages involved in 
repair processes.  Within the M2 population there is also a group of macrophages with 
immunoregulatory and anti-inflammatory properties that are very similar to those of 
resident mucosal macrophages (Biswas and Mantovani, 2010; Geissmann et al., 2010b). 
These “M2-like’ macrophages typically express the scavenger receptor CD163 and the 
mannose receptor CD206, and produce IL-10 as well as tissue remodelling factors such 
as vascular endothelial growth factor (VEGF) and metalloproteinases (Etzerodt et al., 
2010; Fabriek et al., 2007).   Initial studies identified CD163, the scavenger receptor for 
hemoglobin-haptoglobin complexes, as a distinctive M2 marker for macrophages 
(Kristiansen et al., 2001). More recently it has been demonstrated that CD206, the 
macrophage mannose receptor, is up-regulated following IL-4 stimulation (Stein et al., 
1992). M2 macrophages expressing CD206 produce high levels of IL10, but low levels 
of TNF- and IL12  (Fong et al., 2008). 
Moreover recent studies have refined the characterization of intestinal mononuclear 
phagocytes, based on the mutually exclusive expression of CD64 (FcγRI), a marker that 
discriminates macrophages and monocyte-derived dendritic cells from conventional 
dendritic cells (Langlet et al., 2012). It was therefore of interest to analyse the 
expression of these markers on intestinal macrophages in health and disease.  
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4.2 Expression of CD68 by recruited and resident macrophages 
CD68 is the gold-standard marker for macrophages in man.  Therefore CD68 expression 
was analysed on CD33
+
CD14
+
 and CD33
+
CD14
-
 cells. As shown in Figure 4.1, both 
CD33
+ 
CD14
+
 and CD33
+
 CD14
-
 express CD68. In the normal gut 82.4 ± 4.4% of 
CD33
+
 CD14
+
 cells were CD68
+
, in CD 63.5 ± 5.1% were CD68
+
 and in UC 78.3± 
9.0% were CD68
+
.  In the normal colon and UC, most samples were over 80% CD68
+
, 
but the number was consistently lower in CD. Seventy six ± 7.2% of CD33
+
CD14
-
 cells 
were CD68
+
 in normal colon, 60.0 ± 5.4% were CD68
+
 in CD  and 81.2± 9.0%  were 
CD68
+
 in UC. 
 
4.3 CD206 expression on intestinal macrophages 
To explore the hypothesis that there might be a population of M2 macrophages, I 
therefore assessed the expression of CD206 in the CD33
+
CD14
+
 and CD33
+
CD14
-
 
subsets of intestinal macrophages.  
As shown in Figure 4.2, 48.0±10.0% of the CD33
+
CD14
+
 cells in control LPMCs and 
52.0 ± 15.1% in CD samples expressed CD206
+
, whereas in UC  35.0 ± 17.3% of the 
CD33
+
CD14
+
 cells expressed CD206.  
In comparison to CD33
+
CD14
+
 population, the CD33
+
CD14
-
  cells had low expression 
of  CD206 with  13.4 ± 5.0% of CD206-expressing CD33
+
CD14
-
 cells  in control 
tissues , 12.0 ± 6.3% in CD samples  and 6.0 ± 4.0 % in UC samples. 
 
 
 
98 
 
4.4 CD206 expression on blood monocytes 
As was shown in the previous section, in IBD tissue, CD206-expressing CD33
+
CD14
+
 
were increased compared to control subject, therefore the expression of CD206 was 
examined on peripheral blood monocytes from IBD patients and controls (Figure 4.3). 
Blood monocytes from CD and UC patients showed an increased expression of CD206. 
In particular the percentage of CD206
+
expressing CD14
+
CD33
+
 monocytes in CD was 6 
times higher than in controls (control: 10.0 ± 4.0%; CD: 59.0 ± 17.8%) whereas in UC, 
CD206-expressing monocytes were almost 4 times higher than control (37.0±7.0%). 
Moreover the number of CD33
+
CD14
+
CD206
+
 monocytes was significantly different 
between CD (p=0.0283) and UC (p=0.0127) and controls.  
 
4.5 Expression of CD64 by intestinal macrophages  
The majority of CD33
+
CD14
+ 
cells expressed high levels of CD64, as shown in Figure 
4.4. Sixty four ± 8.9% of the cells expressed CD64 in control tissues, 99.6 ± 1.0% 
expressed CD64 in CD tissues and 35.0±17.3% expressed CD64 in UC samples. There 
was a significant difference in the CD64-expressing CD33
+
CD14
+
 between control and 
CD (p=0.0085) and between CD and UC (p=0.0064).  
On the other hand, the analysis of CD33
+
CD14
-
 cells showed a significant increase of 
expression of CD64 in LPMCs from control patients (45.9 ± 10.3%;) compared to CD 
(14.0 ± 2.5%; p=0.0298) and UC (6.0± 2.2%; p=0.0107). 
Since CD64 has been used in both mice and human to distinguish macrophages from 
DCs, CD33
 
negative cells were also investigated for the expression of CD64. 
The graph in figure 4.5 shows the percentage of CD64-expressing CD33
-
 cells in 
control, CD and UC samples. CD64 is virtually absent on the CD33
-
 LPMCs in IBD 
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(CD, 0.5 ± 0.2%; UC, 0.7 ± 0.1%) and is slightly expressed by CD33
-
 cells from normal 
colon (3.8 ± 1.2%). So we can conclude that the majority of CD33
- 
cells in LPMC  are 
not DC’s  . 
 
4.6 CD64 expression on blood monocytes 
In control subjects, nearly 100% of CD33
+
CD14
+
 peripheral blood monocytes displayed 
surface expression of CD64 (Figure 4.6) and there was no difference in the percentage 
of CD64-expressing circulating CD14
+
 monocytes between IBD patients and healthy 
volunteers. 
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4.7 Discussion 
The aim of this chapter was to study phenotypic diversity in gut macrophage markers in 
IBD patients compared to normal subjects and also to study diversity between different 
subsets of macrophages. Therefore CD68, CD206 and CD64 were studied as these are 
well recognised to delineate functional subsets.  
Results showed that intracellular CD68 was highly expressed by CD33
+
CD14
+
 and 
CD33
+
CD14
-
 cells both in control samples and IBD samples. CD206 was equally highly 
expressed on the surface of CD33
+
CD14
+/-
 cells in control subjects and CD compared to 
UC LPMCs but was down-modulated on blood monocytes of healthy volunteers  
compared to  IBD patients. A higher percentage of cells co-expressing CD64 were 
found in the CD33
+
CD14
+   
cells from  control tissues  and CD tissues  and in lower part 
in UC patients compared to the CD33
+
CD14
-
 cells and there were no differences in the 
CD64-expressing blood monocytes between the groups.  
 
 CD33
+
CD14
+
 cells and CD33
+
CD14
- 
cells were mostly CD68
+
 in the normal mucosa 
and in the inflamed mucosa of UC patients, however in Crohn’s disease mucosa, the 
number of CD68
+
 cells was significantly lower. In view of the fact that in the previous 
chapter it was shown that CD68 dominated both in CD and UC mucosa (Figure 3.5), the 
lower proportion of CD68-expressing CD33+ cells, found in CD is not easily explained.  
However examination of the data in Figure 4.1 shows that in all groups there was 
considerable variation between individual patients which may have skewed the mean 
values. We are confident that the CD33
+
 cells were not T cells or DC’s.  
Macrophages are an essential component of the innate immune system and key players 
in the regulation of inflammation. They are also involved in other physiological 
processes such as tissue remodelling. Although they have been studied for many years, 
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the division of these cells into distinct M1 and M2 subpopulations has been investigated 
only recently. The dynamic M1 versus M2 ratio plays an important role in the 
development and resolution of inflammation. M1 cells dominate during the early 
inflammatory phase, whereas M2 cells dominate in the late/repair phase. In chronic 
disease, this normal progression is arrested during the M1 dominant phase, leading to a 
chronic inflammatory response and tissue damage. However studies in the human gut 
are few. 
The classical M2 macrophage CD206 marker was highly expressed in the population of 
CD33
+
CD14
+
 cells, IBD and control mucosa. Gordon proposed to redefine the concept 
of alternative macrophage activation limiting this term to activation by IL-4 and IL-13, 
suggesting that other anti-inflammatory molecules should be regarded as factors which 
deactivate macrophages (Geissmann et al., 2010b). 
Hence, it seems evident that despite the effort to classify in vitro sub-populations of 
macrophages, with different functions, in vivo due to the complexity of intestinal 
immune environment the situation is much more complex.  
CD33
+
CD14
+
CD206
+
 cells could be considered classically activated macrophages 
which lost the pro-inflammatory capacity taking on features of the alternatively 
activated anti-inflammatory macrophages or they could represent a new population of 
cells which do not share any feature between the pro- and the anti-inflammatory feature 
of macrophages.  
Conversely CD33
+
CD14
-
 cells, which do not produce pro-inflammatory cytokines but 
are highly phagocytic in normal gut  (Smith et al., 2001), showed a lower proportion 
expressing CD206, hence most likely these cells may be  anti-inflammatory 
macrophages  in the gut (Sica and Mantovani, 2012).  
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Finally blood monocytes in healthy controls do not express CD206 but blood 
monocytes from CD and UC patients contained a significant proportion of CD206 cells. 
Therefore CD206 expression levels on circulating blood monocytes were significantly 
increased in patients with active IBD compared to blood monocytes from control 
subject. This may reflect the general immune activation seen in IBD patients. 
For the first time the present study reports an increased proportion of 
CD206
+
CD33
+
CD14
+ 
cells in the mucosa of control subjects, CD patients and UC 
patients and as will be shown in the next chapter, we demonstrate that these CD206+ 
cells make TNF-alpha. 
  
One of the aims of this project was selecting a combination of useful markers in order to 
distinguish macrophages population within LPMCs, therefore the markers CD33, CD14 
and CD68 seemed ideal candidates. However CD33 and CD14 markers, although if 
convenient for many reasons, are not completely specific for macrophages, so we were 
aware that CD33
+
 DCs could be contaminating the gut macrophage populations. This 
could also explain why the CD33
+
CD14
+
 and CD33
+
CD14
- 
cells in all patients were not 
entirely CD68
+
.   
The use of CD64 helped to clarify the sub-population within the LPMCs in control and 
IBD subjects. The importance of CD64 as a target molecule to recognise macrophages 
selectivity was showed by Thepen and colleagues (2000), when elimination of CD64-
positive macrophages using the IT H22-RicinA was shown to resolve chronic skin 
inflammation in transgenic mice within 24 h (Thepen et al., 2000). Numerous other 
studies showed that CD64 is constitutively expressed only on macrophages, monocytes 
and their progenitors (van de Winkel and Anderson, 1991). In humanized mice and 
humans, CD64 was highly expressed by HLA-DR
+
 cells that co-expressed CD14; a 
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finding strongly suggesting that high CD64 expression marks cells of monocytic origin 
in humans (Tamoutounour et al., 2012).  
Consistent with these observations, the results presented here showed how a large 
number of CD33
+
CD14
+
 cells in CD and, at less extend, in normal colon express CD64. 
However the fewer percentage of CD64 expressing-CD33
+
CD14
+
 cells found in UC is 
perplexing since it is well documented that this marker is preferentially expressed in 
inflammatory CD14
+
 macrophages in human IBD (Bain et al., 2013). 
 
Moreover CD14
lo
 cells uniformly expressed CD64 in control tissues in contrast to 
CD14
lo
 cells from IBD subjects, which contained fewer cells which expressed CD64. 
This suggest that the CD33
+
CD14
-
CD64
+
 cells in the normal gut are  resident  anergic 
macrophages but that in the inflamed gut they are replaced by CD64- cells.  
In addition blood monocytes (CD14
+
) expressed CD64 both in normal controls and IBD 
patients, hence it can be speculated that while in normal colon and CD, blood 
monocytes in the gut do not lose CD64, in UC once monocytes enter the intestinal 
compartment they may decrease the expression of CD64. While the reason for this 
discrepancy is unclear, it might be related to differences between CD and UC that are 
still, nowadays, poorly understood. Further evidence confirming the specificity of this 
marker for CD64 is showed by the small number of CD64
+
 cells found in the CD33
 
negative gates in normal controls and IBD patients.  
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Figure 4.1: Expression of CD68 by CD33
+
CD14
+
 and CD33
+
CD14
- 
cells. CD33
+
CD14
+
 and 
CD33
+
CD14
-
 intestinal macrophages were analysed for the expression of the intracellular 
marker CD68. A Representative plots identifying CD68 (blue) or control isotype staining (red) 
among CD33
+
CD14
+ 
and CD33
+
CD14
-
 in Control ,CD and UC. B Proportion of CD68 cells 
shown as a percentage of CD33
+
CD14
+ 
and CD33
+
CD14
- 
in Control (n=10), CD (n=6) and UC 
(n=7). Horizontal bars are median values. 
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Figure 4.2: Expression of CD206 by defined subsets of intestinal macrophages. LPMCs 
were isolated from control mucosa and mucosa from CD and UC patients and examined for the 
expression of CD206 (mannose receptor) by flow cytometry. A. Representative dot plots 
showing the CD14
+
 cells (red panel) and resident CD14
-
 cells (green panel) populations. B. 
Results are mean ± SEM and are representative of n=6 (Control), n=5 (CD) and n=5 (UC). 
Horizontal bars are median values. 
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Figure 4.3: CD206-expressing cells are increased in the blood of IBD patients. PBMCs were 
isolated from control, CD and UC peripheral blood. A. Representative dot plots of CD33 and 
CD14. B. Shaded histograms represent staining with the appropriate isotype control. C. 
Proportion of CD206 as a percentage of total CD33
+
CD14
+
. Results are mean ± SEM and are 
representative of of n=5 (Control and CD) and n=3 (UC). *p<0.05. CD versus Control: *p= 
0.0127 and UC versus Control: *p=0.2144. 
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Figure 4.4: CD64-expressing CD33
+
CD14
+ 
and CD33
+
CD14
- 
populations. A. Representative 
dot plots of CD33
+
CD14
+
 and CD33
+
CD14
-
 by live-gated CD45
+
 A. Representative plots 
showing CD64 expression by live-gated CD33
+
 CD14
+
 and CD33
+
CD14
-
 LPMCs. 
 
B. Mean 
percentage of CD64 as a proportion of total live CD33
+ 
CD14
+/- 
LPMCs. Results are mean ± 
SEM and are representative of n=7 (Control), n=5 (CD) and n=5 (UC), *p(Control versus CD)= 
0.0085; ***p(CD versus UC)=0.0064. Horizontal bars are median values. 
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Figure 4.5: CD64-expressing CD33
-
 in control and IBD. A. Representative dot plots of 
CD33
-
 by live-gated CD45
+ 
B. Mean percentage of CD64 as a proportion of total live CD33
- 
LPMCs. Results are mean ± SEM and are representative of n=7 (Control), n=5 (CD) and n=5 
(UC). Horizontal bars are median values. 
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Figure 4.6: CD64-expressing blood monocytes. PBMCs were isolated from Control, CD and 
UC peripheral blood. A. Representative dot plots of CD33 and CD14. Shaded histograms 
represent staining with the appropriate isotype control. B. Proportion of CD64 as a percentage 
of total CD33
+
CD14
+
. Results are mean ± SEM and are representative of  n=3 (Control and CD) 
and n=2 (UC).  
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CHAPTER 5 
Results: Functional analysis of intestinal CD33
+
 LPMCs 
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5.1 Introduction 
It is known that in normal human colon, macrophages are unresponsive to stimuli that 
evoke pro-inflammatory cytokine production in monocytes (Smythies et al., 2005). 
Various reasons have been proposed for this anergy, including lack of CD14, 
rendering the cells unresponsive to LPS, or TGF- made by stromal cells dampening 
pro-inflammatory responses. In IBD, there is a large influx of CD14
+
 monocytes into 
the tissues and interestingly, by immunohistochemistry, Brandtzaeg’s group showed 
that the highest expression of intracellular TNF- was in CD14+ cells (Bjerre et al., 
2000; Bjerre et al., 2003). However many feature of intestinal macrophages remain 
unknown. It is not clear if in inflamed gut CD14
+
 infiltrating monocytes lose CD14 in 
the tissues and become unresponsive.  Likewise with the appreciation that there are 
also wound healing macrophages which express CD206, their role in the gut remains 
unclear. The relative contribution of DCs versus macrophages to TNF- production is 
not known. Finally whether inhibition of ADAM17 increases mTNF- with a reduction 
in secreted TNF- is not known.  In this chapter all of these issues have been 
addressed.  
 
5.2 TNF-α production by peripheral blood monocytes from healthy individuals in 
response to LPS stimulation 
As a positive control, CD14
+
 blood monocytes were stimulated with LPS (100 ng/ml) 
for 4 hours and the expression of the intracellular TNF- in CD14+ cells was determined 
by flow cytometry. 
As shown in Figure 5.1, the number of cells expressing intracellular TNF- in CD14+ 
PBMCs cells increased to 20.6 ± 2.3% compared to unstimulated cells (1.7 ± 0.5%).  
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5.3 TNF-α production by CD33+ LPMCs in response to LPS stimulation 
The percentage of intracellular TNF- expressing CD33+ LPMCs from the normal and 
inflamed colon after activation with LPS was next examined. 
LPMCs from normal colon and inflamed colon were stimulated with LPS for 4 hours 
and assessed for CD33
+
 and TNF-α expression by flow cytometry. The results showed 
no significant increase in TNF- expression in cells from control tissues after LPS (1.3 
± 0.3% without LPS and 1.7 ± 0.6% with LPS, Figure 5.2). On the other hand 4.2 ± 
1.0% of unstimulated CD33
+
 LPMCs from inflamed IBD mucosa showed intracellular 
staining, which significantly increased to 19.0 ± 4.6% when the cells were stimulated 
with LPS for 4 hours (Figure 5.3). 
 
5.4 TNF-α production by CD33+ and CD3+ LPMCs in response to PMA + 
ionomycin stimulation 
PMA and ionomycin was also used to stimulate LPMCs from control and IBD mucosa 
and TNF-α expression was measured in CD33+ macrophages and on CD3+ 
lymphocytes. 
As expected, unstimulated CD33
+
 LPMCs from control tissues (Figure 5.4 A) showed 
less than 1.0 ±0.0 % of cells expressing TNF-α. Activation of CD33+ LPMCs by PMA 
and ionomycin increased the mean expression of TNF-α (15.0 ± 3.2%). 
On the other hand, when inflamed IBD mucosa was studied, CD33
+
 LPMCs which at 
basal level already expressed an higher percentage of TNF- (CD: 8.5 ± 2.1%; UC: 
11.2± 3.4%), compared to CD33
+
 from normal colon (0.8±0.1%), increased the 
intracellular percentage of TNF- after PMA+ionomycin stimuli to 17.0 ±2.2% in CD 
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and 16.0 ± 4.2% in UC (Figure 5.4B), notably also LPMCs from control patients 
increased the expression of TNF- to 13.2±4.8%. 
 
CD3
+
 lymphocytes showed a significant increase in intracellular TNF-α expression 
when LPMCs were stimulated with PMA and ionomycin (25.0 ± 0.8%) compared to 
unstimulated LPMCs (1.3 ±0.4%) (Figure 5.4 C).  
 
5.5 TNF- production by CD33+CD14+ and CD33+CD14- LPMCs 
Having identified two different populations of macrophages which differed in the 
expression of CD14, I hypothesised that there may be heterogeneity in TNF- 
expression between the different subpopulations.  
As shown in Figure 5.5, LPMCs from IBD patients expressed intracellular TNF-α 
without the addition of exogenous stimuli. Notably, the CD33
+
CD14
+
 but not the 
CD33
+
CD14
-
 cells represented the major source of spontaneous TNF-α production. As 
shown in Figure 5.5 A, the frequency of CD33
+
CD14
+ 
TNF-α+   cells in  LPMCs from 
both CD and UC inflamed mucosa was significantly higher (47.3 ± 7.2 %  and 29.6 ± 
6.5%) compared to control  CD33
+
CD14
+ 
TNF-α+ LPMCs (3.1 ± 1.6%).   
The CD33
+
CD14
+
 populations in uninflamed CD mucosa showed a slight increase in 
the number of TNF-  containing cells (8.4 ± 3.4%) when compared to control (0.8 ± 
0.5%). Similarly 23.6 ±16.4 % of CD33
+
CD14
+
 from uninflamed mucosa in UC 
expressed TNF-. 
 
CD33
+
CD14
-
 LPMCs
 
also produced TNF-α, but at lower levels (Figure 5.5B). In 
particular, CD33
+
CD14
-
TNF-α+ LPMCs were significantly increased in inflamed CD 
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mucosa (9.8 ± 2.5%) as well as in  inflamed (13.36 ± 4.9%) and uninflamed UC mucosa 
(5.6 ± 1.93%) when compared to controls (0.75± 0.51%). Moreover there was no 
significant difference between control and uninflamed CD (2.8 ± 1.5%). Also in order to 
have an overall indication of the IBD patient’s medical diagnosis, table 5.1 shows the 
demographics and medical records of the patient populations in the inflammatory bowel 
disease group. 
 
5.6 Correlation between TNF-  expression and CD14 expression in IBD 
 To determine if  intracellular TNF-  expression was related to surface CD14 levels, 
correlation analysis was assessed between the mean fluorescence intensity (MFI) of 
TNF- and the MFI of CD14+ in IBD in a group of 18 IBD patients (11 CD and 7 UC). 
TNF- expression was positively correlated (r=0.63, P= 0.0054) with the expression of 
CD14
+
 in the LPMCs (Figure 5.6). 
 
5.7 TNF-+CD206+-expressing macrophages subsets in IBD 
CD206 is the best known phenotypic marker for M2 macrophages but there is little data 
on intracellular TNF-  within these cells in IBD tissues.  
Surprisingly in CD patients all of the CD206-expressing CD33
+
CD14
+
 cells (which 
represent 48.0 ±15.0 % of overall CD33
+
CD14
+
) were positive for intracellular TNF- 
(Figure 5.7). In UC patients, the mean percentage of TNF--expressing CD33+CD14+ 
CD206
+
 LPMCs was 22.0 ±11.2%. Moreover TNF--expression on CD33+CD14-
CD206
+
 LPMCs in CD was only 4.0 ± 1.5% and in UC was 3.9 ± 2.4%. 
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5.8 TNF-+CD64+-expressing macrophages subsets in IBD 
Using CD64 expression, macrophages can be distinguished from DCs in the intestine of 
both mice and humans and as CD33 is present on both these cell types in the gut, it was 
felt that it would be helpful to look at TNF- expression in CD33+ cells which were 
CD64
+
, being presumably macrophages, or CD64
- 
, which represent DCs (Figure 5.8 B). 
In CD, 26.8 ±13.6% of CD33
+
 CD64
-
 cells were TNF--producing moreover a 
significant larger proportion of TNF- (63.3 ± 19.0%) in CD was produced by CD64+ 
LPMCs (Figure 5.8 C).  
In UC there was a more profound significant difference between the numbers of TNF-  
containing cells in CD64
+
 and CD64
- 
cells (Figure 5.8 D). TNF- containing cells were 
in fact 4 times higher in the CD64
+
 cells (84.2 ± 7.0%) as opposite as CD64
-
 cells (21.0 
±12.4%). 
 
5.9 Membrane TNF- expression on resting CD3+ PBMCs 
The role of ectodomain shedding of TNF- was assessed by the use of an ADAM17-
specific inhibitor, GW280264X, in CD3
+ 
PBMCs from healthy volunteers based on the 
measurement of surface membrane TNF- expression. Hence, to test whether 
GW280264X was a substrate for ADAM 17 protease, PBMCs were stimulated with 
PMA+ionomycin in presence or absence of ADAM 17 inhibitor GW280264X or left 
untreated followed by FACS analysis for mTNF- expression.  
Treatment of PBMCs with PMA+ionomycin resulted in a significant increase of 
membrane TNF- on CD3 lymphocytes. Moreover membrane TNF-+CD3+ cells were 
significantly increased when the cells were stimulated with PMA+ionomycin+ 
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GW280264X (36.8 ± 6.8%) compared to those unstimulated (0.6 ± 0.2%) or stimulated 
with PMA+ionomycin alone (7.4 ± 2.5%) (Figure 5.9). 
I next determined the level of released soluble TNF- in the supernatants after 4 hours 
of culture medium alone, PMA+ionomycin and PMA+ionomycin+GW280264X. 
PMA+ionomycin increased the release of soluble TNF- into the supernatant (465.4 ± 
85.6 pg/ml) compared to unstimulated cells which do not release TNF- (0%). On the 
contrary PBMCs stimulation with PMA+Ionomycin+GW280264X showed significantly 
(p=0.0135) less TNF- production (191 ± 36 pg/ml). 
In addition, the level of soluble IL-8 and IL-6 in the same supernatant was investigated. 
Figure 5.10 show that addition of GW280264X did not inhibit release of these 
cytokines. However it has to be considered that monocytes population, as well as 
lymphocytes, may release TNF- after PMA+ionomycin incubation. 
 
5.10 Membrane TNF- expression on CD3+ and CD33+ IBD LPMCs 
 
The relative expression of membrane TNF- and sTNF- in LPMCs was next 
examined. Increased expression of membrane TNF- was seen in CD3 T cells+ in 
inflamed IBD LPMCs when activated with PMA+ION+DMSO (Figure 5.11).   
In CD and in UC the percentage of membrane TNF- expressing CD3+ T cells 
stimulated with PMA+Ionomycin+GW280264X (Figure 5.11) was  higher (CD: 31.3 ± 
3.3% and UC: 20.2±3.0%) compared to the cells stimulated with  
PMA+Ionomycin+DMSO (CD: 7.6 ± 4.9%; p=0.0576 and UC: 5.1±  1.0% ; p=0.041) 
(Figure 5.11 B-C). 
CD33
+
 LPMCs expressed high level of membrane TNF-  when the cells where 
incubated with the ADAM17 inhibitor. After 4 hours, about 13.0 ± 4.4% of the  CD33
+
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cells in CD and 23.5 ± 4.5% in UC expressed 
 
membrane TNF-+ compared to 
PMA+Ionomycin+DMSO (CD: 3.7 ± 1.3% and UC: 4.0 ± 0.5%) (Figure 5.12 B-C). 
 
5.11 Pro-inflammatory cytokine secretion in the supernatants of LPMCs 
Next, I verified if the increased expression of membrane TNF- on lymphocytes and 
macrophages in LPMC led to a reduced release of the soluble form of the TNF-.  
Stimulation with PMA+ionomycin+DMSO significantly enhanced TNF- production 
by IBD LPMCs (858 ±118 pg/ml) (Figure 5.13). Moreover the addition of GW280264X 
induced a significant decrease of TNF- in the supernatant of LPMCs (32 ± 6 pg/ml) 
compared to PMA+ionomycin+DMSO alone. Conversely  addition of GW280264X did 
not induce any significant change in IL-6 and IL-8  production (888.3 ± 36.5 pg/ml; 
mean 8213 ± 5845 pg/ml respectively) compared to the culture with 
PMA+ionomycin+DMSO (890 ± 14 pg/ml; 10160 ± 7834 pg/ml respectively). 
 
5.12 Pro-inflammatory cytokines in colon explant cultures from IBD patients  
Since GW280264X was observed to inhibit sTNF production by PBMCs and LPMCs 
supernatants, the hypothesis that ADAM10/17 would reduce sTNF and sIL-6R 
production in CD and UC mucosal biopsy cultured ex vivo was tested. 
The spontaneous release of soluble TNF-, sIL-6R, IL-8, IL-6 and IL-1  in the organ 
culture supernatants was measured. GW280264X reduced the concentration of sTNF- 
in CD (67.5 ± 25.5 pg/ml) and UC (117.9 ± 33.9 pg/ml) explant culture supernatant 
compared with DMSO (119.5 ± 57.2 pg/ml  and 214.8 ± 43.8 pg/ml ) (Table 5.2, Figure 
5.14). Spontaneous sIL-6R production was also measured in culture supernatants of CD 
and UC treated with GW280264X or DMSO. 
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GW280264X treated biopsies had a significant reduction in spontaneous sIL-6R 
biopsies production both CD (133.3 ± 36.6 pg/ml) and UC samples (277.9 ± 92.7 pg/ml) 
compared with DMSO (CD: 609.2 ± 151.1 pg/ml; UC: 839.2 ± 267.2 pg/ml). 
On the contrary, no significant differences were found between CD and UC in the 
production of IL-8, IL-1 and IL-6, both in biopsies cultured in vehicle (IL-8: CD 
(35620 ± 7868 pg/ml) and UC (50100 ± 14030 pg/ml); IL-1: CD (39.20 ± 17.58 
pg/ml) and UC (277.5 ± 137.8 pg/ml); IL-6: CD (1900 ± 892 pg/ml) and UC (2957 ± 
1042 pg/ml) and biopsies cultured with  GW 280264X vehicle (IL-8: CD (41210 ± 
15020 pg/ml) and UC (49880 ± 11780 pg/ml); IL-1: CD (47.42 ± 2.260 pg/ml) and 
UC (277.5 ± 137.8 pg/ml); IL-6: CD (2926 ± 1238 pg/ml) and UC (2774 ± 739.0 
pg/ml) (Table 5.2). 
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5.13 Discussion 
Results presented in this chapter suggested that in contrast to monocytes, CD33
+
 
LPMCS from control colon do not make intracellular TNF- when activated with LPS. 
In contrast, LPMCs obtained from affected IBD mucosa spontaneously produced TNF-
 and were further stimulated by LPS to produce greater amounts of this cytokine. On 
the other hand CD33
+
 LPMCs from control colon and IBD colon responded to 
PMA+Ionomycin stimulation, increasing intracellular TNF- production, in the same 
way as lymphocytes.  
In IBD tissues there was a lot more TNF-, both spontaneous and inducible, and the 
highest producers were the CD14
hi
 cells. In addition CD206
+ 
cells in IBD expressed 
intracellular TNF-. The CD64+ marker, used to distinguish DCs and macrophages, was 
highly expressed on the CD33
+
CD14
+
 LPMCs of IBD patients and these cells 
frequently expressed intracellular TNF-.  
 
Results from the second part of the chapter showed that addition of GW280264X, an 
ADAM17 inhibitor, induced increase of membrane-TNF-, both on activated CD3+ 
lymphocytes and CD33
+
 LPMCs, and in parallel sTNF- was reduced in the 
supernatant of cells stimulated with PMA+Ionomycin+GW280264X. IBD biopsies in 
culture produced high levels of TNF- and sIL-6R which decreased by the addition of 
GW280264X while IL-6, IL-8 and IL-1 production were unaffected.  
 
It has previously been shown that blood monocytes CD14
+
 are the principle source of 
macrophages which in healthy gut mucosa are thought to slowly replace senescent 
resident macrophages and to acquire at the same time a profound inflammatory anergy 
(Smythies et al., 2005). Conversely, in IBD patients CD14
+
 cells are abundant in the  
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gut (Grimm et al., 1995), therefore the data presented in this thesis support this notion, 
since CD14
+
 cells, as was shown in the previous chapter, almost absent in normal but 
abundant in  IBD mucosa. 
 
In this study, intracellular TNF- production was compared between CD14+ blood 
monocytes and CD33
+
 LPMCs from normal and inflamed mucosa after stimulation with 
LPS or PMA+Ionomycin. 
Blood monocytes, from healthy volunteers as expected, expressed intracellular TNF- 
after LPS stimulation. However CD33
+
 LPMCs from normal mucosa, which contained 
a number of CD14
low
 cells, under the same condition did not increase the percentage of 
intracellular TNF-.  This suggests that although expressing CD14, these cells may be 
on the pathway to becoming anergic. It is still unclear the mechanism which bring 
intestinal macrophages in a state of 'inflammatory anergy' when they are situated in such 
close proximity to a vast quantities of immunostimulatory material. One of the 
mechanisms proposed, with no clear answer being offered, is that human resident 
intestinal macrophages  lack receptors involved in macrophages  activation, TREM-1 
(Schenk et al., 2005) , complement receptors (CR) 3 and 4, as well as the Fc receptors 
for IgA and IgG (Smith et al., 2001). Moreover, they express anti-inflammatory 
molecules, such as IL-10, and contribute to the differentiation of Treg cells, while 
suppressing DC-derived Th1 and Th17 immunity (Denning et al., 2007). 
 
However when LPMCs from IBD patients, which contain large numbers of CD14
hi
  
cells were stimulated with LPS, the number of cells  expressing intracellular TNF- 
increased. Thus CD14
+
 blood monocytes and CD33
+
 LPMCs from inflamed gut are 
potential responders to the increased inflammatory stimuli as opposite as the CD33
+
 
cells from normal colon.  
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Notably when CD33
+ 
LPMCs from control colon were stimulated with 
PMA+Ionomycin, the number of cells expressing intracellular TNF- dramatically 
increased. This was expected for T cells but not for CD33
+
 cells which were 
unresponsive to LPS. These results suggested that the pathway involving the production 
of TNF- by PMA+Ionomycin-stimulated CD33+ cells is probably not related to the 
pathway activated by LPS. 
It is known that TNF- expression is regulated by transcriptional and posttranscriptional 
mechanisms (Han et al., 1990). The adenine and uridine–rich element (ARE) regulates 
mRNA stability and translation in a way that prevents the pathologic overexpression of 
TNF- (Caput et al., 1986). The importance of this element has been demonstrated in 
transgenic “knockin” mice that lack this cis element (Kontoyiannis et al., 1999) and 
develop chronic inflammatory polyarthritis and inflammatory bowel disease as a 
consequence of TNF- overproduction.  
In a study reported by Saito et al it was shown that TIA-1 regulates the production of 
TNF in LPS–activated macrophages, but not in PMA/ionomycin, or anti-CD3/anti-
CD28–activated T cells (Saito et al., 2001). Therefore the activation cascades triggered 
by LPS and TCR ligation or PMA/Ionomycin might differentially affect the ability of 
TIA-1 to function differently on the CD33
+
 cells. 
 
Analysis of the spontaneous production of TNF- by intracellular cytokine staining 
revealed that the numbers of CD33
+
 TNF-+ cells were increased in the mucosa of 
inflamed IBD.  However there were marked differences in the percentage of TNF- 
containing cells in the different CD33-defined populations. The number of 
CD33
+
CD14
+
 macrophages expressing TNF- was radically increased not only in 
inflamed mucosa but also in uninflamed mucosa of IBD patients. This is perhaps not 
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surprising since it is well established that during the course of IBD there is dramatic 
immune change with intense infiltration of immune cells. 
 
The present study demonstrated that the CD33
+
CD14
+
CD206
+
 cells, both in CD and 
UC, showed high expression of TNF-. This contrasts with  previous studies where 
CD206 macrophages produce high levels of IL10 and low levels of TNF and IL12 
(Gordon and Martinez, 2010). The mechanisms of macrophage phenotypic changes are 
unclear, especially in inflamed human gut. The difficulty is also enhanced by the fact 
that the macrophages activation depend on which stimulation is provided first and also 
whether the activation will be pro- or anti-inflammation is subject to a broad range of 
factors. Stout and Suttles (Stout and Suttles, 2004) raised the hypothesis that 
macrophages could reverse their phenotype and functions depending on their 
microenvironment, hence the results of this study suggest  that macrophage activation is 
plastic and that in IBD mucosa CD33
+
CD14
+
TNF-+ cells represented recruited pro-
inflammatory cells with high activated inflammatory state which expressed also TNF-. 
On the other hand CD33+CD14- cells, may represent a small anti-inflammatory 
percentage of CD206-expressing cells with a little contribute of TNF- expression. 
 
Another important finding was that CD33
+
CD64
+
 LPMC cells, in CD and UC, were the 
larger producers  of TNF- compared to CD33+CD64- cells. This was particularly 
interesting in the light of the finding that CD64-expressing cells were exclusively 
macrophages (Tamoutounour et al., 2012). Indeed the Wojtal group hypothesised that 
Infliximab, one of the anti-TNF- therapeutics approved for use in IBD,  by binding to 
CD64 limits the ability of this drug to block soluble TNF- (Wojtal et al., 2012). This 
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study was in agreement with the finding that Adalimumab and Infliximab bind to Fc 
receptor-expressing THP-1 cells (Arora et al., 2009). 
Is likely that IFX-TNF complexes, which form during neutralization of TNF-, are 
responsible for the limited anti-inflammatory effect via direct activation of Fc receptor 
downstream signalling.  Moreover elevated soluble forms of CD64 have been also 
detected in gut lavage fluid of IBD patients (Hommes et al., 1996), so there is a 
possibility that anti-TNF antibodies which are thought to act in part by interacting with 
Fc receptors and trigger ADCC may be inhibited because the therapeutic antibody is 
complexed to soluble CD64. 
Additionally a conspicuous population of CD33
+
CD64
-
 cells in IBD mucosa, which 
probably were DCs, expressed TNF-. DCs, in contrast to macrophages, are specialised 
antigen-presenting cells that can prime naïve T cells and induce their differentiation in 
inflammatory (eg, Th1, Th17) or Treg phenotypes and similar to macrophages. They 
also accumulate in the mucosa of IBD patients (Hart et al., 2005) and experimental 
models of colitis (Uhlig et al., 2006). Inflammatory DCs also play a critical role in the 
Tbx21
−/− 
Rag2
−/−
 ulcerative colitis (TRUC) model (Garrett et al., 2007). These mice 
spontaneously develop colitis closely reminiscent of human UC.  
Specifically, TNFα secreted from CD103− DCs in TRUC mice potentiated IL-23-
induced IL-17 expression in ILCs, (Powell et al., 2012) whereby neutralisation of 
TNFα, IL-23p19 or IL-17A ameliorated disease (Garrett et al., 2007). 
In human, M-DC8+ DCs, detected in the subepithelial dome of ileal PP M-DC8+ DCs, 
secrete large amounts of TNF-α but not IL-10 upon stimulation LPS suggests that these 
cell types might contribute to the pathogenesis of IBD (de Baey et al., 2003). 
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TNF- is considered to be centrally involved in the pathogenesis of IBD and to play a 
pivotal role in the inflammatory cascade (Papadakis and Roubelakis-Angelakis, 2005). 
As was described in the introduction, to generate soluble TNF-, the membrane- 
associated TNF- is cleaved through the proteolytic activity of ADAM17 (Horiuchi et 
al., 2007). Because many biological effects exerted by TNF- agents, including 
apoptosis and cell-cycle arrest, are mediated by outside-to-inside signalling through 
mTNF (Mitoma et al., 2005) the expression of mTNF, with or without  ADAM17 
inhibitor, on PBMCs and LPMCs was examined. 
Although it has been suggested that other proteinases are capable of TNF- cleavage, it 
has been shown that ADAM17 has the highest affinity for TNF- ectodomain shedding 
among the known substrates (Armstrong et al., 2006).  
Several lines of investigation mainly based on TIMP-3, a family member of the matrix 
metalloproteinase (MMP) family, have showed that TIMP-3 is an endogenous inhibitor 
of ADAM 17 (Schlöndorff et al., 2000). In vitro experiment on timp-3
 -/-
  mice have 
shown that TIMP-3 is able to inhibit inflammatory responses (Smookler et al., 2006), 
and that TIMP-3 deficiency is associated with increased hepatic inflammation due to 
abnormal TACE activity (Murthy et al., 2012). However TIMP-3 is essential for normal 
innate immune function and the loss of TIMP-3 impacts innate immunity by 
dysregulating cleavage of TNF- and its receptors. . 
Nevertheless a series of TIMP-3-based therapies were considered a  novel approaches to 
control inflammation (Newton et al., 2001), in the context of the emergence of new 
agents able to block TNF-  (Billiet et al., 2014).  
In the present study PMA and Ionomycin treatment increased membrane TNF- in 
cultured PBMCs (CD3
+
) and LPMCs (CD3
+
 and CD33
+
) respectively. Moreover TNF-
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 increased on the surface of the cells when the pharmacological inhibitor GW280264X 
was added, as a consequence of the inhibition of ADAM 17 cleavage. 
In addition, the lower systemic inflammatory state generated by GW280264X on the 
LPMCs was reflected by significant reduced level of sTNF- in the supernatants of the 
same cells. Therefore as pre-treatment with GW280264X, but not DMSO alone, 
inhibited the release of sTNF-, was clear that these cells expressed functional 
ADAM17 activity which is responsible for processing mature TNF-a protein. 
There is growing evidence implicating ADAM 17 as an important target in IBD. It has 
previously been shown dysregulation of ADAM17 on the level of gene transcription in 
endothelial barrier dysfunction (Dreymueller et al., 2012) , atherosclerosis (Canault et 
al., 2006) and in in various models of inflammation (Chalaris et al., 2010a; Horiuchi et 
al., 2007; Li et al., 2006; Long et al., 2010).  
 
Organ culture experiments performed with CD and UC biopsies specimens showed that 
decreased amounts of soluble TNF- were detected in IBD biopsies cultured with 
GW280264X.  This is in accord with previous finding where increased levels of 
mucosal mRNA ADAM17 were observed in patients with ulcerative colitis (Brynskov 
et al., 2002) suggesting that higher amount of ADAM17 protease could induce a more 
prominently inhibition by GW280264X.  
The reason why GW280264X increased membrane TNF- in UC biopsies but failed in 
CD biopsies remains unclear but it is reasonable to assume that in most cases of 
complex, immune-mediated disease-including IBD-several pathways are activated and 
contribute to disease and the relative role of these pathways may vary from one patient 
to another.  
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ADAM17 has also been implicated in shedding of a variety of other cell membrane 
substrates including IL-6R (Chalaris et al., 2010b) which is expressed by monocytes, 
macrophages, neutrophils, B-cells, subpopulations of T-cells and non-lymphoid cells 
such as hepatocytes (Chalaris et al., 2010a; Oberg et al., 2006; Scheller and Rose-John, 
2006). In the present study as expected the levels of sIL-6R were significantly decreased 
in the supernatants of IBD biopsies cultured with GW280264X.  
 
These studies suggested that the regulation of ADAM 17 activity and subsequent 
alteration of the soluble TNF- and sIL-6R could have a great impact on IBD 
considering the impact of TNF- on the persistence of the diseases.  
Several monoclonal TNF- antibodies and a soluble TNF- receptor are used for 
clinical practice in immune mediated inflammatory diseases, where they bind to soluble 
and membrane TNF- and can neutralize the pathological effects of TNF-. 
Unfortunately, almost half of IBD patients do not respond to anti-TNF- antibodies and 
the response diminishes with time (Caprioli et al., 2012). Interestingly, clinical therapy 
with adalimumab revealed that patients with high amounts of mTNF cells in the mucosa 
were significantly more likely to respond to anti-TNF- therapy than patients with low 
amounts of mTNF cells (Atreya et al., 2014). This observation opens new paths for 
individualized therapy in IBD suggesting that failure to anti-TNF therapy may occur in 
patients with low amounts of mTNF lamina propria cells due to TNF-independent gut 
inflammation. With this new finding, it might be of interest to target in the future the 
mTNF/TNFR2 interaction rather than total TNF (mTNF plus sTNF) as it has been done 
until now. 
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Disease Gender Age Presentation Disease location 
CD M 19 Uninflamed Ileum 
CD M 32 Uninflamed colon 
CD F 30 Uninflamed Rectum 
CD M 19 Uninflamed Ileum 
CD F 58 Inflamed Ileum 
CD M 60 Inflamed Rectum 
CD F 29 Inflamed Ileum 
CD F 57 Inflamed Ileum 
CD M 28 Inflamed Ileum 
CD F 58 Inflamed Ileum 
CD F 23 Inflamed Ileum 
CD M 19 Inflamed Ileum 
CD  F 23 Inflamed Ileum 
CD F 54 Inflamed Ileum 
CD M 52 Inflamed Ileum 
     
UC M 32 Uninflamed Rectum 
UC M 30 Uninflamed Colon 
UC M 67 Uninflamed Colon 
UC M 18 Uninflamed Colon 
UC F 47 Inflamed Colon 
UC M 51 Inflamed Colon 
UC M 49 Inflamed Colon 
UC F 23 Inflamed Colon 
UC M 30 Inflamed Ileum 
UC F 63 Inflamed Colon 
UC M 32 Inflamed Colon 
UC M 22 Inflamed Rectum 
UC M 18 Inflamed Colon 
 
Table 5.1: Demographic and clinical characteristics of IBD patients: The table shows the 
medical records of patients diagnosed with sever or mild IBD and the location of the tissue 
material taken during endoscopy or surgical resections 
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CD 
 
 
UC 
 
  
DMSO 
 
GW280264X  
 
DMSO   
 
 
GW280264X 
 
TNF- 
 
 
67.50 ± 25.5 
 
119.5 ± 57.1 
 
214.8 ± 43.8 
 
117.9 ± 33.9
**
 
 
sIL-6R 
 
 
609.2 ± 155.8 
 
133.3 ± 36.6
*
 
 
839.2 ± 267.2 
 
277.9 ± 92.7
*
 
 
IL-8 
 
35620 ± 7868 
 
41210 ± 15020 
 
50100 ± 14030 
 
49880 ± 11780 
 
IL-1 
 
39.20 ± 17.5 
 
47.42 ± 2.260 
 
277.5 ± 137.8 
 
163.1 ± 77.9 
 
 
IL-6 
 
1900 ± 892.3 
 
2926 ± 1238 
 
2957 ± 1042 
 
2774 ± 739.0 
 
Table 5.2: Pro-inflammatory cytokines levels in the supernatants of IBD biopsies: TNF-, 
IL-8, IL-1 and IL-6 levels (pg/ml) in the supernatants of DMSO and GW280264X stimulated 
biopsies taken from the inflamed mucosa of CD and UC and cultured for 24 h. Results are mean 
± SEM (**p=0.0016 versus biopsies cultured with DMSO only). 
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Figure 5.1: TNF- expression by CD14+ PBMCs with or without LPS stimulation: CD14+ 
blood monocytes were cultured in medium and LPS (100 ng/ml) in the presence of brefeldine 
for 4 hours. A. Gating strategy used to identify CD14
+ 
PBMCs. 
B. Representative flow cytometry dot plot of TNF-α among four samples analyzed. C. Bar chart 
displaying significatively (p<0.05) higher expression of intracellular TNF-α on the surface of 
CD14
+
 blood monocytes after LPS stimulation for 4 hours. Data are representative of n=4 
experiments.*p=0.0195 versus CTR (medium alone). Bars represent mean percentage of 
expression and error bars denote SEM. 
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Figure 5.2: TNF- expression by control CD33+ LPMCs with or without LPS stimulation: 
LPMCs from control where cultured in medium and LPS (100ng/ml) in presence of brefeldin 
for 4 hours. A. Representative plots showing TNF- expression by live-gated CD33+ LPMCs 
unstimulated and stimulated with LPS. B. Percentage of CD33
+ 
cells expressing TNF- in only 
medium and LPS stimulation. Data are representative of two independent experiments with n=4 
per experiment. Bars represent mean percentage of expression and error bars denote SEM. 
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Figure 5.3: TNF- expression by IBD CD33+ LPMCs with or without LPS stimulation: 
LPMCs from IBD where cultured in medium and LPS (100ng/ml) in presence of brefeldin for 4 
hours. A. Representative plots showing TNF- expression by live-gated CD33+ LPMCs 
unstimulated and stimulated with LPS. B. Percentage of CD33
+ 
cells expressing TNF- in only 
medium and LPS stimulation. Data are representative of two independent experiments with n=4 
per experiment. Bars represent mean percentage of expression and error bars denote SEM. 
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Figure 5.4: CD3
+
 and CD33
+
 LPMCs stimulated by PMA+ionomycin. Representative 
histograms expressing percentage of TNF- as a proportion of total live LPMCs in different 
populations: A. CD33
+
 LPMCs from normal mucosa and IBD mucosa cultured with medium  
B. CD33
+ 
LPMCs from normal mucosa and IBD mucosa cultured with PMA+Ionomycin. TNF-
 expressed in each subsets in presence (continue black line) or absence (solid line) of 
PMA+ionomycin. C. CD3
+
 LPMCs from normal mucosa cultured with medium or with 
PMA+ION  
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Figure 5.5: TNF-α expression by CD33+CD14+ and CD33+CD14-. A. Percentage of 
intracellular TNF- among CD33+CD14+ population in control (n=7) uninflamed CD (n=4), 
Inflamed CD (n=11) Uninflamed UC (n=4) and Inflamed UC (n=4). **p (control versus Infl 
CD) =0.0039; **p (control versus Infl UC) =0.0032. B. Percentage of intracellular TNF- 
among CD33
+
CD14
-
 in the same groups of graph A. *p (control versus Infl CD) = 0.0135; *p 
(control versus Uninf UC) = 0.0122; *p (control versus Infl UC) = 0.0437 
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Figure 5.6: Correlation between TNF- and CD14+: Pearson’s correlation analysis between 
the MFI of TNF- and the MFI of CD14+ .18 IBD mucosa samples were considered (n=11 
inflamed CD and n=7 inflamed UC). **p=0.0054 
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Figure 5.7: Recruited population of macrophages co-express the M2 marker CD206 and 
TNF-: A. Representative plots showing CD206+ expressing TNF- by live-gated 
CD33
+
CD14
+
. B. Percentage of CD33
+
CD14
+
CD206
+
 and CD33
+
CD14
-
CD206
+
 expressing 
TNF-. Data are representative of n=6 per experiment. Bars represent mean percentage of 
expression and error bars denote SEM. 
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Figure 5.8: TNF--expressing CD64+ and CD64- LPMCs in IBD: A. Representative gating 
strategy showing CD33
+
LPMCs gate. B. Representative plot showing CD64
-
 and CD64
+
 C. 
Percentage of TNF-+-expressing CD64- and TNF-+-expressing CD64+ in CD and UC. Data 
are representative of  n=4 per experiment. Bars represent mean percentage of expression and 
error bars denote SEM. *p CD64
+
 cells versus CD64
- 
= 0.0045. 
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Figure 5.9: Expression of membrane TNF- on unstimulated CD3+, PMA+Ionomycin and 
PMA+Ionomycin+ GW280264X (GW) activated CD3+ cells: PBMCs from healthy 
individuals were stimulated with 50 ng/ml of PMA and 500 ng/ml of ionomycin and 10µg/ml of 
GW for 4 hours. A. Gating strategy used to gate positive CD3
+
. B. Representative dot plots 
showing expression of membrane TNF- by FITC-conjugated mouse anti-TNF- monoclonal 
antibody using FACS analysis. C. Proportion of membrane TNF- expression on unstimulated 
CD3
+ 
(medium), PMA+Ionomycin+GW and PMA+ION+GW CD3 stimulated. Data are 
representative of n=6. *p= 0.0298; §§p= 0.0017 versus P+I; ***p=0.0008 versus DMSO. 
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Figure 5.10: Expression of soluble TNF- in the supernatant of stimulated PBMCs: TNF-
, IL-6 and IL-8 cytokines concentration (measured by ELISA) in the culture supernatants 
following PBMCs culture incubated, for 4h,  in the presence of medium with DMSO (0.1%) or 
PMA+ionomycin (P+I) or PMA+ionomycin+GW (P+I+GW) at final concentration of DMSO 
0.1%. Results are mean ± SEM and are representative of n=4 (TNF- and IL-6) and n=3 (IL-
8).*p= 0.0135 versus DMSO; 
†
p= 0.0122 versus DMSO;
 §
p=0.0188 versus P+I.  
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Figure 5.11: Expression of membrane TNF- on activated CD3+ T cells in CD and UC 
LPMCs. A. Representative dot plots showing expression of membrane TNF- by inflamed CD 
(plots above) and UC (plots below) T cells LPMCs. Cells were first stimulated in the presence 
of PMA, ionomycin and DMSO (P+I+DMSO) and PMA ionomycin and GW (P+I+GW) for 4 
hours. A. Proportion of membrane TNF- expression on P+I+DMSO and P+I+GW CD 
stimulated cells. B. Proportion of membrane TNF- expression on P+I+DMSO and P+I+GW 
UC stimulated cells. * p=0.0175. Data are representative of n=2.  
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Figure 5.12: Expression of membrane TNF- on activated IBD CD33+ LPMCs. A.  Flow 
cytometry histogram showing membrane TNF- staining (continue black line) in comparison 
with isotype control antibody (solid line) in CD (upper plots) and UC (lower plots). Cells were 
gated on CD33 LPMCs. Gating strategy for CD33
+
 has been described previously. B. 
Proportion of membrane TNF- expression by P+I+DMSO and P+I+GW stimulated cells in 
CD. C. Proportion of membrane TNF- expression by P+I+DMSO and P+I+GW stimulated 
cells in UC. Data are representative of n=2. 
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Figure 5.13: Effect of ADAM10 and ADAM17 inhibition on cytokine secretion in 
PMA+ionomycin stimulated LPMCs. LPMCs from mucosa of IBD patients were isolated and 
cultured in the presence of PMA+ionomycin+DMSO (P+I+DMSO) or PMA+ionomycin+GW 
(P+I+GW) at final concentration of DMSO 0.1% for 4 hours.  TNF-, IL-6 and IL-8 cytokines 
concentration were measured in culture supernatants by ELISA. Results are mean ± SEM and 
are representative of n=3 **p= 0.0022 versus PMA+ionomycin+DMSO. 
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Figure 5.14: Ex vivo production of TNF-, sIL-6R, IL-8, IL-1 and IL-6. Levels of TNF- 
sIL-6R,IL-8, IL-1 and IL-6 expressed in pg/ml, in the supernatants of intestinal biopsies taken 
from the inflamed mucosa of CD (TNF- n=8; sIL-6R n=5; IL-8 n=7; IL-1 n=5; IL-6 n=6) and 
UC (TNF- n=8; sIL-6R n=9; IL-8 n=8; IL-1 n=7; IL-6 n=9) and cultured for 24h with DMSO 
only or with 10 µM/ml of GW. 
143 
 
 
 
 
 
 
CHAPTER 6 
Results: Gene expression profile of CD33
+
 LPMCs in IBD 
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6.1 Introduction 
CD14
+ 
CD33
+
 macrophages are increased in the gut mucosa of IBD patients. Therefore 
to elucidate possible functional differences, a gene expression array was performed on 
CD33
+
 LPMCs from normal colon and the colon of patients with IBD.  LPMCs were 
isolated from the inflamed colonic mucosa of 11 IBD patients (7 UC and 4 CD) and 
from normal colon of 10 patients and CD33
+ 
cells were purified by MACS.  
Transcripts were grouped in 6 categories: Interferons, Bone Morphogenic Proteins 
(BMPs) and TGF-β Family, PDGF/VEGF Family, TNF Superfamily, and other Growth 
Factors/Cytokines and Interleukins.  
Using +2 and -2 fold change cutoff to define the genes up-regulated or down-regulated, 
71 genes were up-regulated (33 in UC and 38 in CD) and 45 down-regulated (23 in UC 
and 22 in CD) in IBD samples compared to controls.  A complete list of all the genes 
including fold change and p value is listed in the Table 6.1. On the basis of the array 
results, we focused on the genes which were significantly (p < 0.05) down- or up- 
regulated. Twelve genes were differentially expressed in IBD patients compared to 
control subjects (Figure 6.1). These include BMPs and TGF-β Family (BMP2 both in 
UC and CD; BMP5 only in UC), PDGF/VEGF Family (PDGFA only in UC), TNF 
Superfamily (TNFSF8 both in UC and CD), the IL-10 cytokine family (IL10 only in UC 
and IL24 both in UC and CD), the IL1 cytokine family (IL1F5 and IL1F7 both  in UC) 
and also IL13 and IL8 in UC. 
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6.2 Up-regulated genes in CD33
+
 LPMCs from patients with ulcerative colitis 
IL21 was significantly up-regulated in UC samples (p=0.0216) compared to controls, as 
well as IL24 (UC p=0.0194) and the anti-inflammatory cytokine IL-10 (p=0.0307). 
Regarding the TNF superfamily, the only gene in the group to be significantly 
upregulated in UC was TNFSF8 (p=0.046). Finally IL13, IL8 and IL1F5 genes were 
significantly up-regulated (IL13 p=0.0393; IL8 p=0.0415 and IL1F5 p=0.037) (Table 
6.2). 
 
6.3 Up-regulated genes in CD33
+
 LPMCs from patients with Crohn’s disease 
Four genes were up-regulated in CD, particularly IL21 with a 52 fold increase 
(p=0.0498). IL15 was also  up-regulated in CD (p=0.0486), while IL-24 (p=0.0227) and 
TNFSF8 (p=0.049) were also up-regulated (Table 6.2). 
 
6.4 Down-regulated genes in CD33
+
 LPMCs from patients with ulcerative colitis 
Two genes belonging to BMPs family were down-regulated in UC, BMP2 (p=0.0291) 
and BMP5 (p= 0.0061). PDGFA and IL1F7, were also significantly down-regulated in 
UC compared to healthy mucosa (p=0.0422 and p=0.0352 respectively) (Table 6.3). 
 
6.5 Down-regulated genes in CD33
+
 CD LPMCs 
Only one gene, belonging to the BMPs family; BMP2, was significantly down-regulated 
in CD (p=0.0221) compared to control (Table 6.3). 
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6.6 IL-24 mRNA expression in the CD33
+
 LPMCs  
The array analysis unexpectedly highlighted that IL24 transcripts were highly over-
expressed in both CD and UC. RT-PCR for IL-24 on the same samples also showed 
significantly higher (p<0.05) expression of mRNA in UC and CD compared to normal 
colon (Figure 6.2).  
IL24 gene is located in chromosome 1, within a 195-kb cytokine cluster containing the 
IL-10, IL-19, IL-20, and IL-24 genes (Huang et al., 2001) and it shares a 20–30% amino 
acid homology with IL-10, IL-20, and IL-22 and interacts with two different 
heterodimeric receptors, IL-20R1/IL-20R2 and IL-22R1/IL-20R2. Binding to both 
receptors leads to the activation of STAT-3, similar to other members of the IL-10 
family of cytokines (Dumoutier and Renauld, 2002) (Dumoutier et al., 2001). 
Transgenic mice that overexpress IL20, IL22 or IL24 develop skin lesions similar to 
those seen in human psoriasis (Blumberg et al., 2001; Wolk et al., 2009).  Moreover, in 
vivo, IL-24 is predominantly expressed in skin during inflammatory conditions, such as 
psoriasis (Kunz et al., 2006). IL-24 gene expression is also greatly increased at the edge 
of excisional skin wounds (Soo et al., 1999).  
 
IL-24 protein was next measured by ELISA in the supernatants of mucosal biopsies 
from normal colon, inflamed and uninflamed IBD cultured overnight. Higher 
concentrations of IL-24 were found in the supernatants of inflamed biopsies from IBD 
patients (928.5 pg/ml ± 171.3) compared to  uninflamed IBD (584.2 pg/ml ± 145.1) and 
normal samples (273.2 pg/ml ± 37.79) (Figure 6.3). 
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6.7 Effect of recombinant human IL-24 on TNF- production by IBD biopsies 
Biopsies from control and inflamed IBD were cultured for 24 h with recombinant 
human IL-24 and the concentrations of IL-6, IL-8 and TNF- were measured in the 
supernatants. IL-24 significantly increased TNF-  in the supernatants of biopsies from 
IBD patients (436.9 pg/ml ± 115.7) compared to biopsies incubated with medium only 
(119.9 pg/ml± 40.99).  IL-8 and IL-6 were unchanged when biopsies were cultured with 
IL-24 (Figure 6.4). 
 
6.8 TNF- mRNA expression in CD33+ LPMCs  
By PCR array, TNF was increased 3.91 fold in UC and 8.2 in CD fold but this result 
was not statistically significant, so TNF transcripts were quantified in the same CD33
+
 
cells. There was no statistically significant difference in the abundance of this transcript 
between UC and control (p=0.8226).  On the contrary TNF was significantly up-
regulated in CD (p<0.05) compare to the control (Figure 6.5). 
 
 
 
 
 
 
 
 
 
 
 
148 
 
6.9 Discussion 
The main focus of this part of the project was to analyze changes in gene expression in 
macrophages from the inflammatory bowel disease tissues. CD33 was used as a marker 
to purify the cells because the numbers of cells obtained using CD33 and
 
CD14, yielded 
too few cells to perform the experiments. 
 
Among the genes up-regulated in IBD, IL24 expression was significantly elevated both 
at mRNA and protein level. Ex vivo experiments showed that IL-24 protein was higher 
increased in the supernatant of inflamed mucosa of IBD and also recombinant human 
IL-24 induced a significant increase of TNF-  by IBD biopsies cultured ex vivo. 
 
To interpret these findings more clearly, the genes up- and down-regulated will be 
discussed by organizing them into four groups (the groups which did not show 
dysregulated genes are excluded) namely: Bone Morphogenic Proteins (BMPs) and 
TGF-β Family, PDGF/VEGF Family, TNF Superfamily and Interleukins. 
 
While BMP2 expression was down-regulated in both UC and CD, BMP5 decreased 
only in UC. BMPs and their signaling pathway are expressed in normal intestine and 
colon. BMP2, phosphorylated Smad1 and Smad4 are present in mature colonocytes at 
the epithelial surface of normal human and mouse colon (Hardwick et al., 2004). 
Moreover an increase in  BMP2 expression is seen in TNBS-induced colonic 
inflammation resulting in increased epithelial cell proliferation (Maric et al., 2012). 
 
The array showed that most of the genes belonging to the TNF superfamily were up-
regulated in UC and CD, but only TNFSF8, was significantly up-regulated. 
In vivo administration of a TNFSF8 agonist (anti-CD30 mAb) ameliorates oxazolone 
(OXA)-induced colitis, but aggravates TNBS-induced colitis in CD30LKO mice (Sun et 
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al., 2008). The analysis of some of the genes of TNF superfamily which were up-
regulated in CD or UC showed increased expression of TNFSF4 (OX40L). This 
molecule is expressed by dendritic cells and macrophages and serves as a co-stimulatory 
molecule by binding to OX40 on T cells. Although much of the activity of OX40-
OX40L interactions can be attributed to OX40 signalling, OX40L clearly can produce 
functional effects as the production of cytokines such as IL-12, IL-6, IL-1, TNF, and 
IFN-α. How OX40L transmits signals to promote proinflammatory cytokines is not 
known, but some studies have found alterations in PKCβ2, c-Jun, and c-Fos after 
OX40L is cross-linked (Burgess et al., 2004; Matsumura et al., 1999). Moreover, 
blocking the interaction OX40-OX40L ameliorates TNBS colitis in mice and the 
spontaneous colitis seen in IL-2 null mice (Higgins et al., 1999). 
 
The increased production of TNF- protein level by flow cytometry in CD33+CD14+ 
was not confirmed by the results of the array which showed no significant increase for 
UC and CD compared to control. This apparent contradiction can be ascribed to an 
important feature of TNF transcript which are that they are very short lived (< 45 min) 
independent of the activation state of the macrophages, (Mijatovic et al., 2000). 
 Genes from the IL-1 cytokine family as IL-1F5 (IL-36Ra) and IL-1F7 (IL-37), were 
respectively up-regulated and down-regulated in UC and although little is known 
regarding the potential contributions of IL-1 family members in chronic intestinal 
inflammation and gut health, IL-36Ra has been shown to possess an anti-inflammatory 
effect in the brain mediated through a unique TIR8/SIGIRR-dependent pathway 
(Costelloe et al., 2008).  
Interestingly while in UC, IL-37 was significantly down-regulated, in CD it was up-
regulated suggesting that IL-37 dysregulation may play a different role in the two 
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diseases.  IL-37b (which is the most abundant form of IL-37 and the most studied), is 
expressed in the lamina propria of normal colon (Chen and Fang, 2004) and in vitro 
studies on macrophages and epithelial cells overexpressing IL-37b, as well as in  vivo 
experiments in transgenic mice overexpressing human IL-37b, show reduced DC 
activation and decreased production of pro-inflammatory and Th1/Th17 cytokines, 
including IL-1, IL-6, IFN-γ, and IL-17 following LPS stimulation (Nold et al., 2010).  
 
IL15 gene expression was significantly increased in CD array. IL-15 belongs to the IL-2 
cytokine family. The role of IL-15 has been previously investigates  in IBD and it has 
been suggested  that macrophages may be the main producers of IL-15 in IBD patients 
(Liu et al., 2000). Moreover IL-15 together with IL-12 is responsible for the expansion 
of the human intraepithelial ILC1 which produce IFNγ in CD patients (Bernink et al., 
2013).  
 
IL-21 also belongs to the IL-2 family cytokine and in the array IL21 gene expression 
was significantly highly up-regulated both in UC and CD. IL-21 and IL-17, TH17-type 
cytokines were found to mediate pro-inflammatory functions including the up-
regulation of TNF, IL‑1β, IL‑6 and IL‑8, the recruitment of neutrophils and the 
secretion of matrix metalloproteinase by intestinal fibroblasts (Monteleone et al., 2006; 
Monteleone et al., 2005; Siakavellas and Bamias, 2012). 
 
The up-regulation of IL13 in UC was not surprising considered how several studies in 
recent years have highlighted a crucial role of IL-13 in the development of UC. 
Targeting IL-13 has received particular attention as blockade of IL-13 expression and 
function was highly effective in the treatment of experimental colitis. Moreover IL‑13 
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has been shown to promote fibrosis and to cause altered tight junction function and 
apoptosis of IECs thereby driving mucosal ulceration (Heller et al., 2005). 
However the importance of IL-13 as driven cytokine in the disease of UC has recently 
been questioned by Biancheri et al in our lab. It was shown  that IL-13 is not produced 
in excess by mucosal explants or LPMCs from inflamed areas of UC patients in 
comparison to inflamed areas of CD patients and healthy mucosa (Biancheri et al., 
2013a).  
 
The arrays showed also that IL10 was highly expressed in UC but not in CD. The major 
sources of IL-10, an anti-inflammatory cytokine, are macrophages and dendritic cells 
(Paul et al., 2012). Although some other authors showed  increased levels of IL-10 
mRNA in patients with UC but not CD (Peña and Crusius, 1998)  it remains unclear 
why IL-10 is not significantly up-regulated in CD. In UC, IL-10 mRNA expression was 
found to be highly increased in mucosal T cells (Melgar et al., 2003)..  
The increased expression of IL24 in the active lesions of patients with UC and CD 
suggested that IL24 can have a role in mucosal inflammation in IBD; furthermore the 
results from microarray were confirmed by IL-24 PCR, confirming others previous 
results (Ghoreschi et al., 2003).  There were also higher levels of IL-24 protein in 
supernatants of IBD biopsies. 
 
Only a few reports describe the in vivo expression of IL-24 under normal and 
pathological conditions (Soo et al., 1999). One of these studies showed that IL-24 
expression is greatly increased at the edge of cutaneous wounds in an animal model. 
Another study by Kunz et al. (Kunz et al., 2006) showed that IL-24 was expressed by 
keratinocytes from patients with psoriasis.  
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The precise cytokine regulation and molecular mechanisms of IL-24 induction still 
remain unclear but it is known that IL-24 can function either as an intracellular cell 
death-inducing factor in cancer cells, or as a classical  pro-inflammatory cytokine 
signaling through its cell surface receptors, IL-20R1/IL-20R2 and IL-22R1/IL-20R2. 
These receptors complexes have been  studied in the colonic epithelial cells, 
neutrophils, CD4
+ 
cells, CD8
+
  cells and neutrophils (Ma et al., 2011).  
Interestingly, in IBD biopsies cultured with recombinant human IL-24, among various 
cytokines, TNF- was greatly increased, confirming a possible mechanism of 
interaction between IL-24 and the receptors IL-20R1/IL-20R2 and IL-22R1/IL-20R2.  
The use of biopsy organ culture system may more closely approximate ongoing, in vivo 
cytokine production by allowing undisrupted dialogue between intestinal immune cells. 
Moreover, organ cultures include cytokines production from several different intestinal 
sources hence is only possible to speculate the mechanism involving the productions of 
TNF- by IL-24. Binding of IL-24 with two heterodimeric receptor complexes, IL-
20R1/IL-20R2 and, preferentially, IL-10R2/IL-22R1 results in the activation of STAT1 
and STAT3 signalling pathways (Dumoutier et al., 2001). 
Another possible mechanism requires the binding of IL-24 to the receptor dimers 
expressed on Th1 cells which activate and induce TNF- production. 
In conclusion this study provides for the first time a global analysis of human 
macrophages gene expression profiles where genes from inflamed intestinal mucosa 
were compared to uninflamed non-IBD area, providing an important reference point for 
further studies focusing on modulating macrophage activity in chronic inflammatory 
conditions. 
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 UC vs 
control 
CD vs 
control 
UC vs CD 
  
Fold 
change 
 
P value 
 
Fold 
change 
 
P value 
 
Fold 
change 
 
P value 
Interferons: 
 
       
IFNB1 4.0597 0.2683 18.2213 0.0643 4.4883 0.3485 
IFNG -3.3452 0.2202 -2.0148 0.547 1.6603 0.68 
IFNK 16.2625 0.4926 36.1688 0.4625 2.2241 0.8763 
IFNA1 1.7583 0.5552 7.3097 0.0945 4.1572 0.2482 
IFNA8 1.6053 0.4136 2.9779 0.1253 1.8551 0.4015 
IFNA5 -5.4572 0.4877 -13.8291 0.373 -2.5341 0.7637 
IFNA4 -3.9717 0.0752 -3.6978 0.1531 1.0741 0.9395 
IFNA2 3.1455 0.2489 2.607 0.4174 -1.2066 0.8797 
       
Bone Morphogenic Proteins (BMPs) and TGF-β Family: 
       
BMP1 1.1837 0.5547 -1.711 0.1276 -2.0253 0.0631 
BMP2 -3.0781 0.0291 -4.1605 0.0221 -1.3517 0.6234 
BMP3 267.9016 0.2496 -274.5393 0.3328 -1.0248 0.9968 
BMP4 -2.0221 0.243 -2.2628 0.2588 -1.1191 0.8812 
BMP5 -6.0531 0.0061 -1.8972 0.3694 3.1906 0.1328 
BMP6 -9.7945 0.176 -7.763 0.3059 1.2617 0.9114 
BMP7 1.298 0.7213 1.1692 0.8585 -1.1102 0.9103 
BMP8B -3.1975 0.1357 -2.7843 0.2667 1.1484 0.8854 
GDF10 -4.6131 0.2627 3.1185 0.4829 14.3862 0.1303 
GDF11 1.0875 0.803 -1.0622 0.8811 -1.1551 0.7361 
GDF3 -1.6331 0.824 -5.4854 0.5224 -3.3588 0.6664 
GDF5 6.832 0.0518 1.3608 0.7841 -5.0206 0.186 
MSTN -45.4962 0.0835 -137.9421 0.0644 -3.0319 0.6805 
GDF9 -3.2657 0.1091 -2.1327 0.3807 1.5313 0.639 
INHA -1.422 0.7178 -1.4011 0.7729 1.0149 0.9905 
NODAL -2.4468 0.0905 -1.6056 0.4407 1.5239 0.5163 
TGFA -2.0179 0.3243 -3.5883 0.1418 -1.7783 0.5218 
TGFB1 2.0782 0.0871 1.7865 0.2473 -1.1633 0.7719 
TGFB2 1.828 0.3585 2.3263 0.2864 1.2726 0.7706 
TGFB3 -1.1237 0.7887 -1.7126 0.3097 -1.5241 0.4497 
INHBA 22.625 0.0553 24.0037 0.099 1.0609 0.976 
PDGF/VEGF Family 
PDGFA -2.9957 0.0422 -2.999 0.0849 -1.0011 0.9986 
FIGF 1.3612 0.6658 3.4683 0.1574 2.548 0.3089 
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TNF Superfamily: 
LTA 10.0344 0.0862 12.411 0.116 1.2368 0.8968 
LTB 9.1674 0.0661 16.6262 0.0534 1.8136 0.6843 
TNF 3.9069 0.1847 8.1705 0.0935 2.0913 0.5644 
TNFRSF11B 4.4563 0.1956 2.7107 0.4646 -1.644 0.7293 
TNFSF10 -1.4276 0.3731 -1.1258 0.803 1.2681 0.6376 
TNFSF11 11.6094 0.2494 18.4421 0.2538 1.5886 0.8617 
TNFSF12 2.0318 0.148 1.8847 0.2751 -1.078 0.9012 
TNFSF13 -1.0957 0.7888 -1.935 0.119 -1.7661 0.1997 
TNFSF13B 2.6571 0.1007 3.5222 0.0797 1.3256 0.6994 
TNFSF4 4.1705 0.1125 4.3101 0.1721 1.0335 0.9762 
TNFSF8 9.1882 0.0461 13.4177 0.0497 1.4603 0.7713 
CD70 7.056 0.0912 3.92 0.3124 -1.8 0.6779 
TNFSF14 4.5082 0.0605 3.8455 0.153 -1.1723 0.8698 
FASLG -1.0533 0.9311 -1.0588 0.9368 -1.0052 0.9945 
 
Other Growth Factors/Cytokines: 
LEFTY2 -4.3709 0.1149 -2.1477 0.4837 2.0352 0.5382 
CSF1 2.8581 0.1042 2.1254 0.3197 -1.3448 0.7088 
CSF2 28.5522 0.1022 12.9832 0.2871 -2.1992 0.7539 
FAM3B -5.9222 0.5619 -6.3419 0.6155 -1.0709 0.9859 
       
Interleukins: 
IL-10 Family 
 
IL10 4.8668 0.0307 3.8929 0.1107 -1.2502 0.7977 
IL19 18.662 0.3481 8.1478 0.5722 -2.2904 0.8326 
IL22 16.166 0.1087 50.2084 0.0634 3.1058 0.5956 
IL24 4.1236 0.0194 5.2046 0.0227 1.2621 0.7439 
IL20 -3.17 0.5413 -13.9291 0.2517 -4.394 0.5378 
       
IL-1 cytokine family 
IL1A 4.4201 0.1289 4.8766 0.1746 1.1033 0.935 
IL1B 9.255 0.0611 8.7156 0.1228 -1.0619 0.9667 
IL1F8 7.6429 0.3989 194.634 0.0785 25.4659 0.2937 
IL1F5 4.1726 0.037 2.4866 0.247 -1.678 0.5291 
IL1F7 -10.9475 0.0352 1.047 0.9714 11.4619 0.0846 
IL1F9 1.0501 0.9712 -1.232 0.8978 -1.2938 0.8811 
IL1F10 1 1 1 1 1 1 
IL1F6 -1.549 0.3761 -1.549 0.4595 1 1 
       
IL-2 cytokine family 
IL-15 1.3053 0.5405 2.9583 0.0486 2.2664 0.1493 
IL2 -2.8877 0.2272 2.718 0.3391 7.8488 0.0722 
IL21 51.6207 0.0216 52.3679 0.0498 1.0145 0.9943 
IL7 1.4648 0.2846 -1.0678 0.8762 -1.5641 0.323 
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IL-17 cytokine family 
IL17A -2.875 0.6126 -4.0099 0.5794 -1.3948 0.8998 
IL17B 6.9292 0.1969 4.3675 0.4065 -1.5865 0.8045 
IL17C -2.1501 0.369 -2.6148 0.3479 -1.2161 0.8551 
IL25 -1.1596 0.6445 -1.3143 0.4799 -1.1334 0.7587 
       
Other Interleukins: 
IL13 17.5468 0.0393 6.576 0.2392 -2.6683 0.5568 
IL6 14.4195 0.1249 12.2707 0.2239 -1.1751 0.9399 
IL4 1.2459 0.9349 -14.9238 0.4073 -18.5931 0.3979 
IL9 -4.4086 0.4718 -3.6494 0.5997 1.208 0.9421 
IL5 1.9338 0.3301 1.4166 0.665 -1.3652 0.7146 
IL16 1.4207 0.594 1.4057 0.6663 -1.0107 0.9899 
IL12B -5.3743 0.5537 -3.8641 0.6909 1.3908 0.9269 
IL12A -2.0517 0.1933 -1.2658 0.7163 1.6209 0.4843 
IL8 4.1188 0.0415 3.0906 0.1622 -1.3327 0.7303 
IL11 3.3663 0.2226 2.269 0.4866 -1.4836 0.7506 
IL7 1.4648 0.2846 -1.0678 0.8762 -1.5641 0.323 
TXLNA -1.4416 0.38 -2.4787 0.0792 -1.7195 0.3082 
IL3 3.1982 0.1286 1.2853 0.7778 -2.4882 0.3391 
       
       
 
Table 6.1: Gene profiling of the human common cytokines pathway. The expression of the 
84 genes related to the human common cytokines pathway was analyzed employing a qRT-PCR 
based RT2 Profiler TM PCR Array in 11 IBD patients (7 UC and 4 CD) and 10 healthy control 
subjects. The gene expression was normalized to the average expression of 5 housekeeping 
genes (B2 M, HPRT1, RPL13A, GAPDH, ACTB) and directly calculated using the Web-Based 
PCR Array Data Analysis. The table indicates the name and the fold change of all 84 genes, a 
fold change of ≤ 2 indicates a down-regulation, while fold change of ≥ 2 indicates an up-
regulation. The level of statistical significance is set at <0.005. In red and in bold are indicated 
the genes whose expression was statistically significant with respect to the control group. Array 
data were analyzed using average values for control versus UC and CD sample and/or UC 
versus CD.  
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 UC vs control CD vs control 
  
Fold change 
 
P value 
 
Fold change 
 
P value 
TNFSF8 9.1882 0.0461 13.4177 0.0497 
IL10 4.8668 0.0307 3.8929 0.1107 
IL24 4.1236 0.0194 5.2046 0.0227 
IL1F5 4.1726 0.037 2.4866 0.247 
IL-15 1.3053 0.5405 2.9583 0.0486 
IL21 51.6207 0.0216 52.3679 0.0498 
IL13 17.5468 0.0393 6.576 0.2392 
IL8 4.1188 0.0415 3.0906 0.1622 
 
Table 6.2: Genes up-regulated in UC and CD. Genes showing significantly higher expression 
(indicated by a fold change of ≥ 2) in UC and CD compared to control. In red and in bold are 
indicated the genes whose expression was statistically significant (p 0.05) with respect to the 
control group. 
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 UC vs control CD vs control 
  
Fold change 
 
P value 
 
Fold change 
 
P value 
     
BMP2 -3.0781 0.0291 -4.1605 0.0221 
BMP5 -6.0531 0.0061 -1.8972 0.3694 
PDGFA -2.9957 0.0422 -2.999 0.0849 
IL1F7 -10.9475 0.0352 1.047 0.9714 
 
Table 6.3: Genes down-regulated in UC and CD. Genes showing significantly lower 
expression (indicated by a fold change of   2) in UC and CD compared to control. In red and in 
bold are indicated the genes whose expression was statistically significant (p 0.05) with respect 
to the control group. 
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Figure 6.1: RNA isolated from CD33+LPMCs from normal colon and IBD were 
characterized on the Human Common Cytokines RT2 Profiler PCR Array. Fold changes in 
gene expression between CD33
+
 LPMCs are plotted against p-value to produce a volcano plot. 
In the lower position are the genes which showed to be significantly higher (UC ; CD ) and 
significantly lower (UC  ; CD  ) compared to control. In the higher position are shown all 
the other genes. Genes plotted farther from the central blue line have larger changes in gene 
expression. The plot doesn’t include the gene up-regulated more than 52 and down-regulated 
less than -12 fold change. See table 6.3 for all the list of genes. 
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Figure 6.2: Quantitative analysis of IL-24 mRNA expression by CD33
+
 cells. Levels of 
mRNA for IL-24 were analysed by qRT-PCR in control (n=10) UC (n=8) and CD (n=5). 
Results shown are mean expression relative to RLP13A (using the 2
-C(t)
 method) ± SEM.  
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Figure 6.3: IL-24 production assessed by ELISA. Level of IL-24 expressed in pg/ml in the 
supernatants of intestinal biopsies taken from normal colon (n=11), inflamed IBD (CD (n=4) + 
UC (n=4)), Uninflamed IBD (CD (n=7) + UC (n=3)) and cultured for 24h with medium only. 
Results are mean ± SEM (unpaired T-test). All the p value are referred to control (***p=0.0005, 
*p= 0.0432). 
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Figure 6.4: Recombinant human IL-24 increase TNF- release in ex vivo culture: Levels of 
TNF-, IL-6 and IL-8 expressed in pg/ml, in the supernatants of intestinal biopsies taken from 
the inflamed mucosa of 5 CD patients and 6 UC patients (IBD), and cultured for 24h in 
presence of recombinant human IL-24 or with medium only. Bars represent mean ± SEM, 
values relative to medium only *p=0.0273.  
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Figure 6.5: Quantitative analysis of TNF- mRNA expression by CD33+ cells. Levels of 
mRNA for TNF- were analysed by qRT-PCR in control (n=10) UC (n=7) and CD (n=4). 
Results shown are mean expression relative to RLP13A (using the 2
-C(t)
 method) ± SEM. 
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CHAPTER 7 
General discussion and future work 
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The data presented in this thesis provide new information on the changes in colonic 
mucosal macrophages in patients with IBD. I performed phenotypic marker studies, 
functional experiments on the ability of macrophages to produce TNF-, and an 
unbiased gene expression array which altogether allowed to make a number of novel 
observations. 
 
Firstly, I was able to show that CD33, the pan-myeloid marker, can be used to identify 
macrophages both in normal and inflamed IBD mucosa. The additional staining with 
CD14 identified two populations of cells, namely CD33
+
CD14
+ 
cells, which were rare 
in normal mucosa but abundant in IBD mucosa, and CD33
+
CD14
- 
cells, which were, the 
majority in control mucosa. Based on this and previous work, it is likely that the 
CD33
+
CD14
+
 cells are a cell population recently extravasated from blood into the 
inflamed mucosa (Brandtzaeg et al., 1997). Other surface markers were also studied, 
included CD68, CD206 and CD64. CD68 (macrosialin) is a highly glycosylated 
transmembrane protein (Holness and Simmons, 1993), located in the endosomal 
compartment of the cytoplasm. Its function is not known and it is a marker restricted to 
the monocyte/macrophage lineage (Pulford et al., 1990). I showed that CD68 was 
expressed in the majority of CD33
+ 
cells both in control tissues and IBD tissues. We 
were also particularly interested in the expression of M2 marker CD206, which other 
studies have found to be associated with M2 macrophages. M2 macrophages have high 
phagocytic capacity, produce extracellular matrix components and IL-10 (Bohlson et 
al., 2014; Fuentes-Duculan et al., 2010). M2 macrophages clear apoptotic cells, can 
mitigate inflammatory responses, and promote wound healing (Ferrante and Leibovich, 
2012; Sica and Mantovani, 2012). CD206 is a mannose receptor involved in 
phagocytosis of mannose-coated particles, the endocytosis of mannosylated 
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glycoproteins, and in receptor-mediated facilitated antigen presentation (Sallusto et al., 
1995; Tan et al., 1997). There were large numbers of CD206
+
 cells in the CD33
+
CD14
+ 
cells of control and CD mucosa. On the contrary, the number of CD206
+
 cells was 
fewer among the CD33
+
CD14
+ 
cells of UC mucosa. There were very few CD206
+
 cells 
among CD33
+
CD14
- 
cells, both in control subjects and in IBD patients.  
According to current views, monocyte-derived macrophages are characterized by the 
expression of CD64 (Tamoutounour et al., 2012), the high affinity Fcγ type I receptor. 
Consistently with these observations, the results presented here showed that in IBD 
mucosa the number of CD64
+ 
cells was greater in the CD33
+
CD14
+
 cells compared to a 
lower number of CD64
+
 cells found in CD33
+
CD14
-
 cells. In normal controls the 
number of CD64
+
 cells was higher both in the CD33
+
CD14
+
 cells than in the 
CD33
+
CD14
-
 cells. Also, CD64 was present on all blood CD14
+
 monocytes from 
control subjects and IBD patients, which suggest that the down-regulation of CD64 
marker observed in the CD33
+
CD14
-
 cells IBD mucosa may take place when blood 
monocyte enter the intestinal mucosa. 
 
The next part of the thesis focused on the ability of different macrophage subsets to 
make TNF-. The overall conclusion that emerges from this work is that in normal 
mucosa CD33
+ 
cells, which were mostly CD14
-
, do not make TNF- when activated 
with LPS. The low intracellular expression of TNF- in these CD33+CD14- cells may 
be the result of endotoxin tolerance. In contrast, CD33
+
 cells from IBD mucosa, which 
contain large numbers of CD14
+
 cells, displayed an increased expression of intracellular 
TNF- after activation with LPS. Also, we observed a significant statistical positive 
correlation between the MFIs for TNF- and CD14+, in  cells from IBD mucosa, 
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suggesting  that loss of CD14 may be a way by which infiltrating macrophages regulate 
excessive TNF production. 
 
Of particular interest is the observation that CD33
+
CD14
+
CD206
+
 cells in inflamed 
mucosa from both CD and UC patients showed high levels of intracellular TNF-. On 
the contrary, CD33
+
CD14
-
CD206
+
 cells showed only little expression of intracellular 
TNF-. Furthermore, the increasing CD206+ cells in CD14+ blood monocytes may 
indicate that in IBD there is selective recruitment of blood CD14
+
CD206
+
 monocytes 
leading to an overall increase in the proportion of intestinal CD14
+
CD206
+
 
macrophages which make TNF- in IBD. This is clearly different from previous studies 
where CD206
+
 macrophages were shown to produce high levels of IL-10 and low levels 
of TNF- and IL-12 (Gordon and Martinez, 2010). Hence, despite the effort to define 
the function of CD206
+
 cells, the data presented here showed that CD206 does not 
represent a reliable marker to identify M2 macrophages in tissues.  
 
Another important finding is that in CD and UC patients, CD33
+
CD64
+
 cells were more 
frequently positive for TNF- compared to CD33+CD64- cells. Additionally, in IBD 
mucosa a conspicuous population of CD33
+
CD64
- 
cells, which were probably DCs, 
expressed TNF-. The role of DCs in human IBD has not been fully elucidated. Studies 
have found an increased number and maturation of DCs within inflamed IBD tissue 
(Kaser et al., 2004) and others have suggested enhanced recruitment of immature DC 
into inflamed tissue (te Velde et al., 2003). DC from inflamed Crohn’s disease lamina 
propria express higher levels of CD40 than DC from non-inflamed Crohn’s disease or 
from healthy control tissue (Stagg et al., 2003). Moreover elevated levels of CD40 
returned to normal following treatment with anti-TNF-. These findings on isolated 
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cells are consistent with immunohistological studies showing increased numbers of DC 
expressing CD40, CD86, (Vuckovic et al., 2001), CD83 (Ikeda et al., 2001) and CD80 
(te Velde et al., 2003) in mucosal tissue from Crohn’s disease and ulcerative colitis 
patients. 
In addition, M-DC8
+
 monocytes, which were possible precursor of DCs, secrete large 
amounts of TNF-α but not IL-10 upon stimulation with LPS suggested that DCs may 
contribute to the pathogenesis of IBD (de Baey et al., 2003).  
In mice, inflammatory CD11c
high
HLA-II
+
 CD11b
+
CD103
-
 DCs predominantly produced 
TNF-α which synergises with IL-23 to drive IL- 17A production by ILCs (Powell et al., 
2012). Additionally, colitis in TRUC mice is characterized by dysregulated transcription 
of TNFα by colonic DCs (Garrett et al., 2007).  
 
Proteolytic cleavage of membrane-anchored TNF- (mTNF-) into soluble TNF- by 
ADAM17/TACE (TNF- converting enzyme), the most important sheddase for mTNF-
α, plays an important role in regulating TNF- activity (Monteleone et al., 2012). Work 
in this thesis showed that culturing LPMCs with an ADAM10/17 inhibitor increased 
membrane TNF- in activated CD3+ lymphocytes and CD33+ LPMCs, and in parallel 
reduced the release of soluble TNF- into the supernatants of the same cells. T cells 
from ADAM17 knock-out mice produce 90% less soluble TNF-α than T cells from wild 
type mice (Locksley et al., 2001), and consistent with this in our study, treatment with 
an ADAM10/17 inhibitor strongly suppressed the level of TNF- and sIL-6R (another 
substrate of ADAM17) released into the supernatant of inflamed biopsies from CD and 
UC patients cultured ex vivo. Hence, ADAM17 inhibition has the ability to inhibit the 
cleavage process of mTNF-α and suppress the production of soluble TNF-α, therefore it 
might be a promising strategy to prevent TNF-α-related diseases. However, further 
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studies are needed to investigate all the consequences of ADAM17 inhibition, as a loss-
of-function mutation in ADAM17 was identified in two of three children born to 
consanguineous parents and was associated to inflammatory skin and bowel disease 
(Blaydon et al., 2011). 
 
In the last part of the thesis we investigated the gene expression profile of macrophages 
isolated from IBD samples. Among all the genes up- (TNFSF8, IL21, IL10, IL1F5, IL13 
and IL-8) or down-regulated (BMP2, BMP5, PDGFA and IL1F7) in IBD, IL24 was one 
of the most highly up-regulated gene in IBD macrophages. In addition, IL-24 protein 
was also increased in supernatants of IBD biopsies cultured ex vivo. The precise 
cytokine regulation and molecular mechanisms of IL-24 induction is still unknown. IL-
24 mRNA expression is significantly increased in the inflamed mucosa of patients with 
IBD (Andoh et al., 2009). The up-regulation of IL-24 in patients with CD and patients 
with UC could reflect a similar pathophysiological mechanism which accounts for the 
induction of this cytokine in the two forms of IBD. Other studies showed that IL-24 
expression is greatly increased at the edge of cutaneous wounds in an animal model or 
in keratinocytes from patients with psoriasis (Bernink et al., 2013; Kunz et al., 2006). 
Furthermore, data in this thesis showed that TNF- was increased in the supernatants of 
biopsies cultured with recombinant human IL-24. In contrast, treatment of IBD biopsies 
with recombinant human IL-24 did not change the production of other cytokines, such 
as IL-6 and IL-8. However, whether IL-24 can selectively induce the secretion of TNF-
 awaits further studies. Although IL-24 is a member of the IL-10 superfamily (Chada 
et al., 2004), it differs from IL-10 in that the latter inhibits NF-κβ activation (Wang et 
al., 1995), whereas IL-24 enhances TNF-induced NF-κβ activation. Since NF-κβ is 
hyper activated in IBD LPMCs (Atreya et al., 2008; Coskun et al., 2011), it is likely that 
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induction of IL-24 in the gut of patients with CD and patients with UC is driven by 
these signaling pathways. Overall, these results show that IL-24 may have an important 
role in mucosal inflammation in IBD. 
 
Future work 
Possible future studies should focus on determining if neutralizing IL-24 in mucosal 
biopsies cultured ex vivo inhibits pro-inflammatory cytokine production and/or 
investigating some of the other up-regulated genes identified in the array. For example, 
IL-21 produced by T cells has been shown to be important in mouse and human gut 
inflammation (Monteleone et al., 2005), and yet it was markedly increased in 
macrophages. 
 
Moreover the gene expression array provides new evidence regarding the IL-1F5 
(Interleukin 36 Receptor Antagonist; IL-36Ra) gene which was significantly up-
regulated in UC and CD CD33
+
 cells. Among the few published papers regarding IL-
36Ra function, it has been shown that IL-36Ra has an anti-inflammatory effect localized 
to the brain and mediated through a unique TIR8/SIGIRR-dependent pathway 
(Costelloe et al., 2008). Hence, on the basis of the limited availability of published data 
and our preliminary findings, IL-36Ra may potentially play an important role in IBD. 
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